

1 DNA variants affecting the expression of numerous genes in *trans* have  
2 diverse mechanisms of action and evolutionary histories

3 Sheila Lutz<sup>1</sup>, Christian Brion<sup>1</sup>, Margaret Kliebhan<sup>1</sup>, Frank W. Albert<sup>1,\*</sup>

4

5 <sup>1</sup>Department of Genetics, Cell Biology, & Development, University of Minnesota, Minneapolis,  
6 MN, USA

7

8 \* Corresponding author

9 E-mail: [falbert@umn.edu](mailto:falbert@umn.edu) (FWA)

10

## 11 **Abstract**

12 DNA variants that alter gene expression contribute to variation in many phenotypic traits. In  
13 particular, *trans*-acting variants, which are often located on different chromosomes from the genes  
14 they affect, are an important source of heritable gene expression variation. However, our  
15 knowledge about the identity and mechanism of causal *trans*-acting variants remains limited. Here,  
16 we developed a fine-mapping strategy called CRISPR-Swap and dissected three expression  
17 quantitative trait locus (eQTL) hotspots known to alter the expression of numerous genes in *trans*  
18 in the yeast *Saccharomyces cerevisiae*. Causal variants were identified by engineering  
19 recombinant alleles and quantifying the effects of these alleles on the expression of a green  
20 fluorescent protein-tagged gene affected by the given locus in *trans*. We validated the effect of  
21 each variant on the expression of multiple genes by RNA-sequencing. The three variants were  
22 strikingly different in their molecular mechanism, the type of genes they reside in, and their  
23 distribution in natural populations. While a missense leucine-to-serine variant at position 63 in the  
24 transcription factor Oaf1 (L63S) was almost exclusively present in the reference laboratory strain,  
25 the two other variants were frequent among *S. cerevisiae* isolates. A causal missense variant in the  
26 glucose receptor Rgt2 (V539I) occurred at a poorly conserved amino acid residue and its effect  
27 was strongly dependent on the concentration of glucose in the culture medium. A noncoding  
28 variant in the conserved fatty acid regulated (FAR) element of the *OLE1* promoter influenced the

29 expression of the fatty acid desaturase *Ole1* in *cis* and, by modulating the level of this essential  
30 enzyme, other genes in *trans*. The *OAF1* and *OLE1* variants showed a non-additive genetic  
31 interaction, and affected cellular lipid metabolism. These results revealed remarkable diversity in  
32 the molecular basis of *trans*-regulatory variation, highlighting the challenges in predicting which  
33 natural genetic variants affect gene expression.

## 34 **Author summary**

35 Differences in the DNA sequence of individual genomes contribute to differences in many traits,  
36 such as appearance, physiology, and the risk for common diseases. An important group of these  
37 DNA variants influences how individual genes across the genome are turned on or off. In this  
38 paper, we describe a strategy for identifying such “*trans*-acting” variants in different strains of  
39 baker’s yeast. We used this strategy to reveal three single DNA base changes that each influences  
40 the expression of dozens of genes. These three DNA variants were very different from each other.  
41 Two of them changed the protein sequence, one in a transcription factor and the other in a sugar  
42 sensor. The third changed the expression of an enzyme, a change that in turn caused other genes  
43 to alter their expression. One variant existed in only a few yeast isolates, while the other two  
44 existed in many isolates collected from around the world. This diversity of DNA variants that  
45 influence the expression of many other genes illustrates how difficult it is to predict which DNA  
46 variants in an individual’s genome will have effects on the organism.

## 47 Introduction

48 DNA variants that alter gene expression are an important source of genetic variation for many  
49 traits [1], including common disease in humans [2], agricultural yield [3,4] and evolutionary  
50 change [5]. To map gene expression variation in the genome, expression levels are measured in a  
51 population of individuals and related to the genotype of each individual. This approach identifies  
52 expression quantitative trait loci (eQTLs) – genomic regions that each contain one or more variants  
53 that affect gene expression.


54 eQTLs can be classified into two types based on their mechanism of action. *Cis* eQTLs arise from  
55 variants that alter the expression of genes on the same DNA molecule, for example by changing  
56 the sequence of a regulatory element in a promoter. Most *cis*-acting variants are located close to  
57 or within the genes they influence, such that *cis* eQTLs can be detected as “local” eQTLs that  
58 overlap the given gene. By contrast, *trans* eQTLs arise from variants that change the activity and/or  
59 abundance of a diffusible factor which in turn alter the expression of other genes. *Trans* eQTLs  
60 can be located anywhere in the genome relative to the genes they affect. While they can be local  
61 (e.g., if a gene encoding a transcription factor resides next to a gene targeted by that factor), most  
62 *trans* eQTLs are “distant” from the genes they affect, usually on different chromosomes.

63 As in genetic mapping of other traits, identifying the specific DNA variants that have causal effects  
64 in eQTL regions is challenging. Recent studies have made progress in identifying *cis* acting  
65 variants (e.g. [6–10]). However, few *trans*-eQTLs have been resolved to single variants. This is  
66 although most of the heritable contribution to gene expression variation arises from *trans* rather  
67 than *cis* eQTLs [11–16], and although *trans* acting variation is likely to play pivotal roles in  
68 shaping diseases and phenotypes within species [11,17]. Identifying the molecular nature of *trans*-  
69 acting variants and the mechanisms by which they alter gene expression is key to understanding  
70 the connection between genotypic and phenotypic variation.

71 Natural isolates of the yeast *Saccharomyces cerevisiae* have provided fundamental insights into  
72 the genetics of gene expression variation ([12,18–34], reviewed in [35]). Particularly intensive  
73 efforts have been directed at the comparison between a laboratory strain (the genome reference  
74 strain S288C, or “BY”) and a wine strain (RM11a, “RM”), whose genomes differ at about 40,000  
75 variants. eQTL mapping in recombinant progeny from a cross between these strains revealed the  
76 existence of eQTL hotspots that each influence the expression of numerous genes in *trans* [18].

77 Many of these hotspots also affect protein levels [22,36,37]. Recently, an analysis of mRNA levels  
78 in an expanded set of 1,012 BY/RM progeny provided a more comprehensive view of regulatory  
79 variation in this cross [12]. Specifically, *trans*-acting variation arose almost exclusively from 102  
80 hotspots, some of which affected the expression of thousands of genes (Fig 1A). A small number  
81 of hotspots in this and other crosses have been resolved to their causal genes and nucleotide  
82 variants [18,20,23,30,31,34,38–41], but progress towards a more complete view of hotspot  
83 variants has been hampered by the challenges of engineering and measuring the expression effects  
84 of candidate variants.

85



86

87 **Fig 1. Hotspot fine mapping strategy.** A. Illustration of the possible *cis* and *trans* effects at an eQTL hotspot.  
88 A genomic region, shown in blue with several genes depicted as wide arrows, harbors multiple variants  
89 (stars). Of these, one causal variant (red star) alters the activity and/or abundance of a gene product (blue  
90 circle with red star), which alters the expression of multiple genes (gray arrows) in *trans*. Another variant is  
91 shown affecting a neighboring gene in *cis*, but has no *trans* effect. B. A schematic showing two examples of  
92 engineering a BY allele (blue) to an RM allele (red) using CRISPR-Swap. In step one, a non-essential gene is  
93 replaced by the G418 resistance cassette (KanMX) or an essential gene is flanked by the hygromycin  
94 resistance (hphMX) and KanMX cassettes. In step two, the strain is transformed with the CRISPR-Swap  
95 plasmid pFA0055 that expresses Cas9 and the guide RNA gCASS5a and the auxotrophic marker LEU2; and  
96 a PCR-generated repair template containing the desired RM allele. The gCASS5a/Cas9 complex directs  
97 cleavage (scissors) of the cassettes. Either a single-cut or a double-cut occurs depending on the number of  
98 cassettes present. Selection of transformants for leucine prototrophy and loss of G418, or hygromycin and  
99 G418, resistance identifies strains with the desired RM allele replacement. C. Quantifying the expression of  
100 a representative gene affected in *trans* by a hotspot. Fluorescence of the protein expressed from the GFP-  
101 tagged gene and optical density (OD<sub>600</sub>) of the culture are measured in 15 minute intervals during growth  
102 in a plate reader. The inflection point, the point where the culture exits logarithmic growth, and two  
103 flanking points are used to determine the GFP/OD<sub>600</sub> ratio for phenotyping the effect of the engineered  
104 alleles.

105

106 Here, we describe a strategy for the identification of causal eQTL hotspot variants that combines  
107 a genome engineering approach with high-throughput quantification of fluorescently tagged  
108 protein expression as a phenotypic readout. We used this strategy to identify causal variants  
109 underlying three *trans*-acting eQTL hotspots in the BY and RM strains: a common missense  
110 variant in the glucose receptor Rgt2, a rare missense variant in the oleate-activated transcription  
111 factor Oaf1, and a common variant in the promoter of *OLE1* that alters the expression of this  
112 essential fatty acid desaturase gene. We studied the effects of these variants in more detail and  
113 discovered that the effect of the *RGT2* variant is influenced by the environment, and that the *OAF1*  
114 and *OLE1* variants interact in a non-additive fashion and lead to changes in cellular lipids. These  
115 results show that variants underlying *trans*-acting hotspots are highly diverse. They can be  
116 common or rare in the population, different in their evolutionary conservation, and located in the  
117 coding or noncoding region of genes encoding functionally diverse proteins.

118 **Results**

119 **The CRISPR-Swap strategy for engineering allelic series**

120 To assist fine-mapping of hotspot intervals, we devised “CRISPR-Swap” (Fig 1B), a two-step  
121 strategy for efficient allele exchange that combines advantages of “insert-then-replace” methods  
122 [42,43] with CRISPR/Cas9 engineering [44–46]. In the first step, a given locus is replaced with a  
123 selectable marker cassette. Second, the strain is transformed with a plasmid that expresses Cas9  
124 and a guide RNA (gRNA) that targets the cassette, along with a DNA repair template containing  
125 terminal homology to sequences flanking the cassette in the genome. We designed the “gCASS5a”  
126 gRNA to specifically target a sequence shared by several selectable marker cassettes used for gene  
127 deletions in the popular pFA6a series (e.g., KanMX6, natMX4 and hphMX4; [47–50]; S1 Fig)  
128 such that the same gRNA can be used to replace each of these cassettes. By inserting two different  
129 cassettes flanking a genomic region, this gRNA can be used to exchange both cassettes along with  
130 the intervening sequence. This “double-cut” CRISPR-Swap method enables allele exchange even  
131 when the region contains sequences essential for survival (Fig 1B). Additionally, we designed a  
132 “gGFP” that specifically targets cassettes used for C-terminal tagging of open reading frames with  
133 GFP.

134 The gRNA/Cas9 complex is constitutively expressed from the CRISPR-Swap plasmid and will  
135 continue to cleave at the cassette(s) in the genome until a repair is made that abolishes the gRNA  
136 recognition sequence or the cell dies. Consequently, after transformation, all colonies that form on  
137 media lacking leucine have undergone a repair that blocks further cleavage by the gRNA/Cas9  
138 complex. We designed the gCASS5a and gGFP gRNAs to cleave in the cassette but outside of the  
139 selectable marker gene, such that marker expression should be maintained if repair occurs without  
140 exchange of the selectable marker (Figure S1). Thus, transformants with the desired allele swap  
141 can be easily identified by screening for the loss of the resistance or auxotrophy conferred by the  
142 selectable marker.

143 We analyzed the results of 40 independent CRISPR-Swaps we performed to determine the  
144 efficiency of CRISPR-Swap. After transformation with the CRISPR-Swap plasmid expressing  
145 either gCASS5a or gGFP and a PCR-generated repair template, a median of 87.5% of the  
146 transformants no longer expressed the cassette selectable marker. We screened over 100 of these  
147 transformants for integration of the desired allele by colony PCR, restriction digestion or

148 sequencing and found that all had the correct allele exchange. We also sequenced the guide RNA  
149 recognition site in 13 transformants that remained G418 resistant and found that 2 had the  
150 hallmarks of repair by non-homologous end-joining, while the remaining 11 were repaired using  
151 the homologous sequence present in the GFP-His3MX cassette in these strains (see below) to  
152 repair the locus. We observed no difference in CRISPR-Swap efficiency among the two strain  
153 backgrounds (BY and RM), the genomic loci we targeted, or the gCASS5a and gGFP gRNAs. In  
154 summary, CRISPR-Swap readily creates allele replacements with high efficiency.

155

156 **Fine-mapping of hotspot regions using GFP-tagged proteins to measure *trans*-gene  
157 expression**

158 We leveraged the ability of CRISPR-Swap to rapidly engineer allelic series at a given locus to  
159 dissect three *trans*-acting hotspot regions to the causal variant. We focused on these hotspots  
160 because they have strong effects on many genes in *trans*, and because earlier fine-mapping in the  
161 1,012 BY/RM segregant panel had located them to only a few genes. Before engineering each  
162 hotspot, we selected one abundantly expressed gene strongly affected by the hotspot in *trans* to  
163 monitor the effects of our genome edits on its gene expression (Fig 1C). We C-terminally tagged  
164 the open reading frame of this gene with GFP, engineered the hotspot locus with CRISPR-Swap,  
165 and measured GFP fluorescence in each engineered strain during growth on a 96-well plate reader  
166 (Methods). This approach provided high-throughput measurements of gene expression for the  
167 statistically powerful dissection of the hotspot loci.


168

169 **A missense variant in *RGT2* influences expression of *HXT1* in *trans***

170 A hotspot locus on chromosome IV affects the expression of many genes at the mRNA and protein  
171 levels in crosses between BY and RM [12]. In the expanded BY/RM segregant panel, this locus  
172 had been mapped to a region containing three genes: *RGT2*, *ARF2*, and *RPL35-B* (Fig 2A). There  
173 mRNA levels of 1,400 genes are affected by this hotspot in *trans*, and these genes are enriched for  
174 roles in ATP synthesis and carbohydrate derivative metabolism. The strongest *trans* effect was on  
175 *HXT1* mRNA (LOD = 182), which encodes a low affinity glucose transporter whose expression is  
176 affected by Rgt2 [51], suggesting *RGT2* is likely the causal gene at this hotspot. In support of this,

177 genetic variation within the *RGT2* coding region was previously shown to influence protein levels  
178 of the high affinity glucose transporter Hxt2p [29]. *RGT2* encodes a low affinity glucose sensor  
179 located in the plasma membrane (Fig 2B; reviewed in [52]). The BY and RM alleles of *RGT2*  
180 differ at five missense single nucleotide variant (SNVs). Three of these SNVs are located in the  
181 long cytoplasmic-facing C-terminal tail required for glucose signaling, and the remaining two are  
182 within the 12 predicted transmembrane helices (Fig 2B). *RGT2*, as well as *ARF2*, is also influenced  
183 by a local eQTL.

184



185

186 **Fig 2. Fine mapping the causal variant in *RGT2*.** A. Schematic of the eQTL hotspot on Chromosome IV. From  
 187 top to bottom, the figure shows the hotspot location on the chromosome and the number of genes it  
 188 affects, the positions of the BY and RM sequence variants (gray lines mark synonymous and intergenic  
 189 variants and orange lines mark missense variants), the genes and their positions in the hotspot (large gray  
 190 arrows; red outlines denote genes with a local eQTL) The 90% confidence interval (light blue), 95%

191 confidence interval (medium blue) and the position of markers perfectly linked to the hotspot peak marker  
192 (dark blue). B. Schematic of the Rgt2 protein in the plasma membrane. BY / RM missense variants are  
193 indicated by stars, with the identified causal variant in red. The missense variant amino acid positions, their  
194 resulting amino acid change and their PROVEAN scores [53] are shown. The synonymous variants are not  
195 depicted. C. On the left are schematics of *RGT2* alleles with BY sequences in blue and RM sequences in red.  
196 Positions of SNVs are marked with a straight line and INDELs are marked with two diagonal lines. The  
197 variants in the *RGT2* 3'UTR and synonymous variants are not depicted. On the right are the corresponding  
198 Hxt1-GFP fluorescence levels for each allele. P-values are for tests comparing each allele to its respective  
199 wildtype. Significant p-values are outlined. Blue boxplots indicate alleles in the BY background and red  
200 boxplots and gray background shading indicate alleles in the RM background. Lines group measurements  
201 of the same clone. Different symbols (circles, squares, etc.) denote different plate reader runs. Small dots  
202 next to a clone indicate a 5'UTR indel with an allele that does not match the one indicated in the allele  
203 schematics (see Methods).

204

205 To determine if *RGT2* is the causal gene at this hotspot and identify the responsible variant, we C-  
206 terminally tagged Hxt1 with GFP and created a series of allele replacements at the *RGT2* locus  
207 using CRISPR-Swap. In both BY and RM backgrounds, deletion of *RGT2* drastically reduced  
208 Hxt1-GFP levels, confirming that *RGT2* is required for proper Hxt1-GFP expression. Replacing  
209 the BY *RGT2* promoter region with the RM allele had no measurable effect on Hxt1-GFP.  
210 Reciprocal allele replacement of the entire *RGT2* coding region showed that the *RGT2* RM allele  
211 resulted in lower Hxt1-GFP expression compared to the BY allele (Fig 2C), which is the direction  
212 of effect expected from eQTL data [12].

213 By engineering a series of chimeric *RGT2* alleles spanning the coding region we systematically  
214 narrowed the causal region to two missense variants, neither of which were predicted to be  
215 deleterious (Fig 2C; S1 Table). Of these, a G-to-A SNV at 241,965 bp, resulting in a valine to  
216 isoleucine change at amino acid position 539 (V539I), recapitulated the effect of swapping the  
217 entire coding region. In a strain that carried all *RGT2* RM coding variants *except* V539I, Hxt1-  
218 GFP expression was indistinguishable from the BY wildtype, suggesting that V539I is the single  
219 causal variant in this gene. The effect of V539I on Hxt1-GFP expression was present in both BY  
220 and RM (Fig 2C), with no evidence that the strain background influences the effect of this variant

221 (interaction p-value = 0.1). The variant caused a minor effect on growth rate in the RM  
222 background, but no effect in the BY background (Table 1).

223

224 **Table 1. Effects of causal hotspot variants on growth rates**

Variant	Growth rate in BY (RM allele relative to BY wildtype allele)	p-value in BY	Growth rate in RM (BY allele relative to RM wildtype allele)	p-value in RM
RGT2(V539I)	98%	0.5	93%	0.02
OAF1(S63L)	96%	0.09	100%	>0.99
OLE1(FAR)	92%	0.3	92%	0.005

225


226

227 **The *RGT2* V539I variant affects Hxt1-GFP expression in a glucose-dependent manner**

228 Increasing glucose concentrations results in an increase in the expression of Hxt1 [51]. Given that  
229 the V539I variant lies within one of the predicted transmembrane helices that likely form the  
230 pocket necessary for glucose sensing by Rgt2 [54], we hypothesized that the effect of the V539I  
231 variant may change depending on the concentration of glucose in the culture medium. To test this  
232 idea, we measured Hxt1-GFP expression in BY and RM strains with their native *RGT2* alleles as  
233 well as with engineered V539I alleles in a range of glucose concentrations (Fig 3).

234

235



236

237 **Fig 3. Effect of the *RGT2* I539V variant on Hxt1-GFP expression in different glucose concentrations.** Hxt1-  
238 GFP fluorescence levels in the four different genotypes in increasing glucose concentrations are shown.  
239 Blue boxplots indicate alleles in the BY background and red boxplots and gray background shading indicate  
240 alleles in the RM background. Lines group measurements of the same clone. Different symbols (circles,  
241 squares, etc.) denote different plate reader runs. The inset graph shows fitted effect sizes as a function of  
242 glucose concentration. Error bars show standard errors of the mean. P-values are shown for ANOVA models  
243 examining the various main and interaction terms.

244

245 In both BY and RM, higher glucose concentrations increased expression of Hxt1-GFP regardless  
246 of which V539I allele was present. However, the difference in Hxt1-GFP expression between the  
247 V539I alleles showed a clear dependence on glucose levels (ANOVA test for interaction between  
248 allele effect and glucose concentration:  $p = 7e-13$ ). The BY allele drove nearly 2-fold higher Hxt1-  
249 GFP expression than the RM allele at 1% glucose, while the difference between alleles became  
250 almost indistinguishable at 12% glucose. Thus, the effect size of the V539I variant underlying the  
251 *RGT2* eQTL hotspot strongly depends on the environment.


252

253

254 **A missense variant in *OAF1* alters expression of *FAA4* in trans**

255 Several of the eQTL hotspots identified in the BY/RM cross affect the expression of genes  
256 involved in fatty acid metabolism. They include a hotspot on chromosome I, which affects the  
257 mRNA and protein levels of 450 genes in *trans*. The locus was previously mapped to a region  
258 containing the genes *FLC2* and *OAF1* [12] (Fig 4A). Neither *FLC2* nor *OAF1* are influenced by a  
259 local eQTL, suggesting the causal variant is likely coding. *OAF1* encodes a transcription factor  
260 that activates expression of genes involved in peroxisome related functions including the  $\beta$ -  
261 oxidation of fatty acids [55–57], making it a promising candidate causal gene. The BY and RM  
262 alleles of *OAF1* differ at three missense SNVs (Fig 4B).

263



264

265 **Fig 4. The *OAF1* causal variant.** A. Schematic of the eQTL hotspot on Chromosome IV. From top to bottom,  
266 the figure shows the hotspot location on the chromosome and the number of genes it affects, the positions  
267 of the BY and RM sequence variants (gray lines mark synonymous and intergenic variants and orange lines  
268 mark missense variants), the genes and their positions in the hotspot (large gray arrows; red outlines  
269 denote genes with a local eQTL) The 95% confidence intervals (medium blue) and the position of markers  
270 perfectly linked to the hotspot peak marker (dark blue).B. Schematic of the Oaf1 protein domains and  
271 variants. The conserved zinc-finger domain and the ligand-binding domain [58] are in orange. BY / RM  
272 missense variants are indicated by stars, with the identified causal variant in red. The missense variant  
273 amino acid positions, their resulting amino acid change and their PROVEAN scores [53] are shown. The  
274 synonymous variants are not depicted. C. The figure shows Faa4-GFP fluorescence levels for strains with  
275 the indicated *OAF1* (L63S) alleles. P-values are for tests comparing the allele to its respective wildtype. Blue

276 boxplots indicate alleles in the BY background and red boxplots indicate alleles in the RM background. Lines  
277 group measurements of the same clone. Different symbols (circles, squares, etc.) denote different plate  
278 reader runs.

279


280 We engineered a series of *OAF1* alleles and measured Faa4-GFP expression in *trans*. *FAA4*  
281 mRNA abundance was shown to be strongly affected by this locus (LOD score = 102, [12]), and  
282 *FAA4* encodes a long chain fatty acyl-CoA synthetase, a protein with clear phenotypic connection  
283 to fatty acid metabolism. We found that a single T-to-C missense variant in *OAF1* at 48,751 bp  
284 resulted in a decrease in Faa4-GFP expression in agreement with the direction of effect observed  
285 in the eQTL data (Fig 4C, S2 Fig, S1 Table). The variant encodes a leucine at position 63 in BY  
286 and a serine in RM (L63S). In the Oaf1 protein, the L63S variant is located next to the Zn(2)Cys(6)  
287 DNA binding domain (Fig 4B) where it may alter Oaf1 binding to its regulatory targets. The effect  
288 of L63S on gene expression was consistent in both strain backgrounds (interaction p-value = 0.4;  
289 Fig 4C), and L63S had no detectable effects on growth rate (Table 1).

290

### 291 **A noncoding promoter variant influences *OLE1* expression in *cis* and *FAA4* in *trans***

292 A second fatty-acid related hotspot resides on chromosome VII and affects the mRNA levels of  
293 977 genes, which are enriched for functions in lipid biosynthetic processes as well as the response  
294 to endoplasmic reticulum stress. The confidence interval of this locus spans ~1 kb centered in the  
295 noncoding region between the *SDS23* and *OLE1* genes (Fig 5A). *OLE1* encodes the ER-bound Δ9-  
296 fatty acid desaturase, the only yeast enzyme capable of desaturating fatty acids [59,60]. *SDS23* is  
297 likely involved in regulation of the metaphase to anaphase transition of the cell cycle [61]. Given  
298 the enrichment of target genes of this hotspot involved in lipid metabolism, we reasoned that *OLE1*  
299 is the more likely causal gene. The BY and RM alleles of *OLE1* differ at one missense SNV and  
300 four non-coding variants (2 indels and 2 SNVs) in the *SDS23* and *OLE1* intergenic region.

301



315

316 We engineered the essential *OLE1* locus using double-cut CRISPR-Swap, by flanking the region  
317 with the HphMX and KanMX cassettes and replacing both cassettes along with the intervening  
318 region with a series of alleles (Fig 1B). We again measured Faa4-GFP expression in the engineered  
319 strains, given *FAA4* mRNA levels are strongly affected by this locus (LOD = 78). We identified a  
320 noncoding A-to-G SNV at 398,081 bp in the intergenic region between *SDS23* and *OLE1* that  
321 affected Faa4-GFP expression in the expected direction based on the eQTL data (S3 Fig, S1 Table).  
322 This effect was consistent in both strain backgrounds (interaction p-value = 0.8). While the BY  
323 allele of this variant decreased growth rate in the RM background, the variant had no effect in the  
324 BY background (Table 1).

325 The causal variant is located in the fatty-acid regulated (FAR) promoter element, a region known  
326 to be important for transcriptional activation and fatty acid regulation of *OLE1* expression [62]  
327 (Fig 5B). Both *OLE1* and *SDS23* are strongly affected by local eQTLs with higher mRNA  
328 expression linked to the BY allele, suggesting that *OLE1* and/or *SDS23* expression may be affected  
329 by the FAR variant. To test the effect of the FAR variant on *OLE1* expression, we created BY  
330 strains with *OLE1* tagged with mCherry in addition to *FAA4* tagged with *GFP*. In these strains,  
331 the RM FAR allele significantly decreased Ole1-mCherry levels in *cis* and increased Faa4-GFP  
332 *levels in trans* (Fig 5C), which are the directions of effect expected based on the eQTL results [12].

333 To further examine the *cis*-regulatory activity of the FAR variant, we created reporter plasmids  
334 with multiple alleles of the *SDS23/OLE1* intergenic region driving expression of yeVenus. When  
335 the intergenic region drove expression of yeVenus in the direction of *SDS23*, the promoter alleles  
336 all drove similar yeVenus expression (S4 Fig). In sharp contrast, when the intergenic region drove  
337 expression of yeVenus in the direction of *OLE1*, the FAR-BY allele drove significantly higher  
338 yeVenus expression than the RM allele, fully recapitulating the difference between the all-BY and  
339 all-RM promoter alleles (S4 Fig). The effect did not depend on whether the yeVenus plasmids  
340 were expressed in the BY or RM background (interaction p > 0.29). Together, these results suggest  
341 that the FAR variant influences *OLE1* in *cis*, as well as *FAA4* in *trans*.

342

343


344

345 **Small changes in *OLE1* expression from wildtype levels are sufficient to affect *FAA4* gene  
346 expression in *trans***

347 To explore the effect of *OLE1* and *SDS23* abundance on gene expression in *trans*, we added an  
348 additional copy of *OLE1*, *SDS23* or the intergenic sequence on a single-copy plasmid in a BY  
349 *FAA4-GFP* strain. The presence of an extra copy of *OLE1* resulted in significant reduction of Faa4-  
350 GFP levels, consistent with eQTL data (S5 Fig). By contrast, an extra copy of *SDS23* resulted in  
351 an increase in Faa4-GFP levels. An extra copy of the intergenic sequence alone did not change  
352 Faa4-GFP levels (S5 Fig). These results further support that it is a change in *OLE1* and not *SDS23*  
353 expression that is responsible for the *trans*-effect of the hotspot on *FAA4* expression.

354 While changes in Ole1 levels appear to be the primary cause for the *trans* effect on Faa4-GFP, the  
355 noncoding FAR variant alters *OLE1* expression by only about 15% (Fig 5B). To understand the  
356 relationship between *OLE1* and *FAA4* over a range of expression levels, we inserted a synthetic,  
357 inducible  $Z_3EV$  promoter upstream of *OLE1*. This promoter can be activated precisely and  
358 quantitatively by addition of estradiol to the culture medium [63]. We measured both Ole1-  
359 mCherry and Faa4-GFP as a function of estradiol concentration and observed a clear  
360 anticorrelation between Ole1-mCherry and Faa4-GFP levels (Fig 6). At an estradiol dose of 4 – 5  
361 nM, the  $Z_3EV$  strain expressed Ole1-mCherry and Faa4-GFP at levels comparable to BY strains  
362 expressing *OLE1-mCherry* from its native promoter with either the wildtype or FAR-RM allele.  
363 Higher doses of estradiol continued to increase Ole1-mCherry levels, while Faa4-GFP dropped  
364 rapidly and reached a plateau at levels well below the native BY strains. As expected for the  
365 essential *OLE1* gene, low levels of induction resulted in poor growth (S6 Fig). Notably, growth of  
366 the  $Z_3EV$  strain was closest to wildtype at 6 nM estradiol and higher, a concentration in which  
367 *OLE1* expression levels are well above wildtype levels. The reason for this growth defect at  
368 wildtype expression levels is unknown and may reflect an inability of strains with the  $Z_3EV$   
369 promoter and C-terminal mCherry fusion to finely regulate *OLE1* transcription. Taken together,  
370 our results indicate that the BY strain expresses *OLE1* at a level at which even slight alterations in  
371 *OLE1* expression, like that caused by the FAR variant, are sufficient to change *FAA4* expression  
372 in *trans*.

373



374

375 **Fig 6. Expression modulation of Ole1.** Fluorescence levels of Ole1-mCherry (solid red lines) under control  
376 of the estradiol-inducible  $Z_3EV$  promoter and Faa4-GFP (solid green lines) under its native promoter at  
377 various estradiol doses. Fluorescence levels of strains with the native *OLE1* promoter and the FAR-BY or  
378 FAR-RM allele respectively, are shown as dotted and dashed lines, respectively, at each estradiol  
379 concentration for comparison. All strains harbor both the mCherry tag on Ole1 and the GFP tag on Faa4.

380


381

### 382 **A non-additive interaction between the *OAF1* and *OLE1* variants**

383 The Oaf1 transcription factor binds throughout the *OLE1* promoter including in the close vicinity  
384 of the FAR variant [64]. This raises the possibility that the effects of *OAF1* L63S and the FAR  
385 variant may interact with each other genetically. While neither variant had shown significant  
386 interactions with the genetic background as a whole (see above), a specific interaction between  
387 these two variants could have been obscured by the thousands of other sequence differences  
388 between the BY and RM backgrounds. Indeed, the previous eQTL data contained a non-additive  
389 interaction affecting *FAA4* mRNA levels between two *trans* eQTLs that contained *OAF1* and  
390 *OLE1*, respectively (Fig 7A). To test if this *trans*-by-*trans* interaction could be explained by the  
391 specific causal variants we identified here, we constructed a BY strain that carried the RM alleles  
392 at both *OAF1* and the FAR variant and compared its Faa4-GFP expression to strains that carried  
393 one or the other of these edits. The combined alleles resulted in Faa4-GFP expression that differed  
394 from an additive allele combination (interaction  $p = 0.002$ ) in a manner that mirrored the detected

395 eQTL interaction (Fig 7B). Specifically, in the presence of the more active RM *OAF1* allele, the  
 396 FAR variant showed a greater effect than in the presence of the less active BY *OAF1* allele. As  
 397 with the majority of epistatic interactions identified in this cross [65], the deviation from additivity  
 398 caused by this interaction is detectable but subtle.

399 To test if this *trans*-by-*trans* interaction affecting *FAA4* could be mediated by a *cis*-by-*trans*  
 400 interaction between the same two variants, we introduced our yeVenus plasmids with the two FAR  
 401 alleles into BY strains with either the BY or RM *OAF(L63S)* alleles. We again found a significant  
 402 interaction between the FAR and *OAF1* variants (Fig 7C). In the presence of the *OAF1*-L63S-RM  
 403 allele, the FAR variant resulted in a larger difference in yeVenus expression than in the presence  
 404 of the *OAF1*-L63S-BY allele ( $p = 1.5 \text{ e-7}$ ). The *OAF1* RM allele also resulted in overall higher  
 405 expression of the yeVenus construct ( $p = 1.6 \text{ e-6}$ ). Taken together, these results show that the  
 406 *OAF1* L63S variant and the *OLE1* FAR variant interact genetically such that their effects on gene  
 407 expression in *cis* as well as *trans* are not simply additive.




408

409 **Fig 7. Nonadditive genetic interaction between the *OAF1* and *OLE1* causal variants.** A. Data from [12] show  
 410 levels of *FAA4* mRNA in 1,012 BY/RM segregants, divided into four groups depending on their genotypes at  
 411 *OAF1* and *OLE1*. Note the slightly larger difference between *OLE1* alleles in segregants that carry the RM  
 412 allele (red boxplots) compared to the BY allele (blue boxplots) at *OAF1*. B. *Faa4-GFP* fluorescence levels in  
 413 strains engineered to carry the BY or RM allele at *OAF1*-L63S and *OLE1*(FAR). C. *yeVenus* fluorescence levels  
 414 for strains engineered to carry the BY or RM allele at *OAF1*-L63S and the *OLE1*(FAR) promoter driving  
 415 *yeVenus* expression on a plasmid. The difference between *OLE1* alleles in segregants (in A) or strains (in B  
 416 and C) that carry the RM allele (red boxplots) compared to the BY allele (blue boxplots) at *OAF1* are  
 417 highlighted by gray arrows.

418

419 **The *OAF1* and *OLE1* variants alter lipid profiles**

420 To test if the two causal variants in the fatty acid metabolism genes *OAF1* and *OLE1* alter cellular  
421 phenotypes other than gene expression, we measured overall lipid composition as well as non-  
422 esterified (“free”) fatty acids (NEFAs) in the RM and BY strains, as well as in BY strains with  
423 *OAF1(L63S)-RM*, *OLE1 FAR-RM*, or both of these alleles (Fig 8 & S7 Fig). The BY and RM  
424 strains differed in multiple metabolites (S7 Fig, S2 Table, S3 Table), and the presence of either of  
425 the two variant alleles in the BY background also resulted in significant differences in lipid  
426 metabolites. The BY *OAF1* allele decreased the fraction of longer-chain (C18) lipids (Fig 8A) and  
427 also caused a decrease in the amount of C18 NEFAs (S7 Fig). This change resembles the effect of  
428 an *OAF1* deletion on lipid metabolism [64], consistent with the BY *OAF1* allele having reduced  
429 function (S2 Fig). The *OLE1* FAR-RM allele resulted in a significant increase in the amount of  
430 saturated NEFAs but did not significantly reduce the amount of desaturated NEFAs (Fig 8B). This  
431 suggests that reduced expression of the Ole1 desaturase caused by the FAR-RM allele results in  
432 reduced consumption of the substrate but maintains levels of the reaction product in the reaction  
433 catalyzed by Ole1. We did not detect changes in overall lipid composition due to the *OLE1* FAR-  
434 RM allele. Taken together, our results show that the variants affecting *OLE1* expression and Oaf1  
435 activity translate to changes in cellular lipids.




437 **Fig 8. Lipid and fatty acid measurements.** A. The fraction of C18 lipids in BY strains with wildtype or RM  
438 alleles at *OAF1(L63S)* or *OLE1(FAR)* or a combination of both. B. The concentration of saturated and  
439 unsaturated non-esterified fatty acids (NEFA) in the same strains. For each strain, the figure shows values  
440 for each replicate (smaller points) along with the mean (larger points) and standard deviation (vertical  
441 lines). See S7 Fig for all measurements.

442

#### 443 **The fine-mapped variants are the cause of the hotspot effects on mRNA levels**

444 We have shown that each of the variants in *RGT2*, *OAF1*, and the *OLE1* FAR element affect the  
445 protein expression of a representative gene in *trans*. If these variants underlie the *trans*-acting  
446 hotspots, we expect them to alter the transcript levels of many genes, and that these expression  
447 changes will correlate with the known effects of the hotspots we sought to fine-map. To test this,  
448 we quantified transcript levels in BY strains edited at each variant (S4 Table – S6 Table).

449 Each of the three variants altered the transcript levels of dozens of genes including the  
450 representative gene we used for fine-mapping (*HXT1* or *FAA4*) with the expected direction of  
451 effect (Fig 9, Table 2). In addition, the FAR variant caused a nominally significant ( $p = 0.03$ ) effect  
452 on *OLE1* but not on *SDS23* ( $p = 0.7$ ), in agreement with our yeVenus reporter assay (S4 Fig).  
453 Crucially, the magnitude of expression change caused by the three variants was significantly and  
454 positively correlated with the respective hotspot effects (Fig 9) when considering all expressed  
455 genes. Like the vast majority of *trans* eQTLs [12], the three hotspots dissected here have small  
456 effects on most genes, typically explaining only a few percent of variance in mRNA levels. Our  
457 RNA-Seq experiment was not designed to detect such small effects at statistical significance,  
458 which would require dozens to hundreds of replicates. When we used a lenient significance cutoff  
459 (uncorrected  $p < 0.05$ ) to restrict our analysis to genes with some evidence for differential  
460 expression, the correlations with hotspot effects increased at each hotspot (Table 2). These strong  
461 correlations were reflected in high directional concordance. For example, at a more stringent  
462 threshold (false discovery rate = 10%), every differentially expressed gene had concordant  
463 direction of effect with the given hotspot for *RGT2* and *OLE1*, and there was just a single  
464 discordant gene (out of 30) for *OAF1* (Fig 9). This strong agreement between expression changes  
465 caused by the three variants and known hotspot effects shows that these variants are causal variants  
466 at their respective hotspots.



467

468 **Fig 9. Comparison of the differential gene expression caused by each causal variant and the eQTL hotspot**  
469 **effects.** The differential expression of an edited vs wildtype strain is on the x-axis and the previously  
470 determined hotspot effects are on the y-axis. All genes with non-zero hotspot effects are shown. Red points  
471 are genes with differential expression  $p < 0.05$ . Purple points are genes with differential expression  
472 at  $FDR < 0.1$ . The larger red circles mark the genes used for fine-mapping. The blue circles are genes we  
473 investigated in the confidence interval of each hotspot. The correlation between differential expression  
474 and hotspot effects is given in each panel. For RGT2, orange circles show adenine-metabolism related genes  
475 that are described in the text.

476

477 **Table 2. RNA Seq results**

Variant	Number of DE genes (10% FDR)	Number of DE genes ( $p < 0.05$ )	Correlation <sup>1</sup> between DE <sup>2</sup> and hotspot effect: all genes	Correlation <sup>1</sup> between DE <sup>2</sup> and hotspot effect: genes with DE $p < 0.05$
RGT2 (V539I)	45	183	$Rho = 0.30, p = 2e-25$	$Rho = 0.64, p \approx 0$
OAF1(L63S)	45	147	$Rho = 0.62, p = 1e-46$	$Rho = 0.80, p = 6e-15$
FAR	18	95	$Rho = 0.34, p = 1e-19$	$Rho = 0.48, p = 0.0015$

478 <sup>1</sup>These correlations exclude genes without a hotspot effect detected in [12].

479 <sup>2</sup>log2 fold change

480

481 If a hotspot is caused by multiple causal variants in the same or neighboring genes, our single  
482 variant edit might not account for all the effects of the hotspot. Therefore, we examined genes with


483 transcript levels strongly affected by the hotspot that are unaffected by our variant edits. Genes  
484 strongly affected by the hotspot at *RGT2* but not by the *RGT2 V539I* variant showed a significant  
485 enrichment for “*de novo* IMP biosynthetic process” (corrected p = 9e-9) and related terms in purine  
486 metabolism. This enrichment is driven by seven ADE genes with large hotspot effects that were  
487 all non-significant in our experiment (Fig 9). We suspect that a second variant in this region is  
488 responsible for these effects.

489

#### 490 **Population distribution and conservation of causal variants**

491 To explore the evolutionary history of the three causal hotspot variants, we examined their  
492 distribution across a worldwide panel of 1,011 *S. cerevisiae* isolates with genomic sequence [66].  
493 The BY allele at *OAF1* L63S is rare among yeast isolates (Fig 10). It is carried only by BY and a  
494 few close relatives while the RM allele is present in all other isolates as well as related species.  
495 Reflecting this pattern, the Protein Variation Effect Analyzer (PROVEAN) tool [53] assigned a  
496 “deleterious” score of -5.4 to the BY allele at this variant. In our experiments, the BY *OAF1* allele  
497 increased Faa4-GFP expression, which was the same direction caused by the *OAF1* knockout (S2  
498 Fig). Thus, the *OAF1* hotspot is caused by a rare, derived missense variant almost exclusive to the  
499 BY laboratory strain that probably reduces function of the Oaf1 transcription factor.

500



501 **Fig 10. Population genetic features of the causal variants.** Neighbor joining tree of the 1,011 *S. cerevisiae*  
 502 strains sequenced in [66]. For each causal variant, the presence of the BY (blue), RM (red), BY and RM  
 503 (purple), or other (black) allele is shown across the tree. For the *OAF1* and *RGT2* missense variants, amino-  
 504 acid alignments with the indicated species are shown. For the intergenic FAR variant, we show nucleotide  
 505 alignments as well as PhastCons conservation scores for the depicted *SDS23* / *OLE1* region from the UCSC  
 506 Genome Browser.  
 507

508  
 509 The *RGT2* and *OLE1* variants show very different patterns. At *RGT2* V539I, both the valine in BY  
 510 and the isoleucine in RM are also encoded by related yeast species (Fig 10). Evidently, the V539I  
 511 variant can be tolerated without severe fitness consequences, as reflected in a “neutral” PROVEAN  
 512 score of 0.12. Within *S. cerevisiae*, the highly divergent and likely ancestral group of Chinese  
 513 isolates [66–68] carry the valine found in BY, suggesting that the isoleucine in RM is derived.  
 514 This derived allele has ~25% frequency in the *S. cerevisiae* population, where it is predominantly  
 515 found in isolates from the European wine clade, as well as in a second group of isolates with mixed  
 516 origin (Fig 10). Both the derived RM variant and an *RGT2* deletion resulted in reduced induction  
 517 of *HXT1* expression (Fig 2C).

518 At the *OLE1* FAR variant, the alanine found in BY is present in the ancestral Chinese isolates,  
519 suggesting that the guanine in RM is derived (Fig 10). Indeed, the nucleotide sequence of the  
520 noncoding region surrounding the FAR variant is conserved among *Saccharomyces sensu stricto*  
521 species, and all other species carry the alanine found in BY at this position. The RM allele has  
522 high frequency (46%) among yeast isolates, predominantly due to near fixation among the many  
523 isolates in the European wine clade. The allele is also present in isolates from dairy, ale beer, and  
524 other origins. The RM allele increased *FAA4* expression in *trans*. This is the same direction of  
525 effect we observed when inserting the kanMX cassette immediately downstream of *OLE1*. Such  
526 engineered alleles are commonly called “Decreased Abundance by mRNA Perturbation” (DAmP)  
527 alleles and are expected to decrease gene function by lowering mRNA transcript levels ([69]; S3  
528 Fig).

529 Thus, the three causal variants identified here have diverse population genetic characteristics. They  
530 include a rare, lab-specific allele and two common alleles found in a quarter or more of the  
531 sequenced yeast isolates. At all three variants, we observed that the likely derived allele altered  
532 gene expression in the same direction as alleles that eliminate or reduce gene function.

533 **Discussion**

534 We fine-mapped natural DNA variants that each result in expression changes at many genes in  
535 *trans* using CRISPR-Swap, a strategy that facilitates rapid engineering of allelic series at a given  
536 locus. CRISPR-Swap is similar to other recently developed two-step engineering approaches  
537 [70,71], and has multiple advantages: 1) The great majority of clones that are transformed with the  
538 CRISPR-Swap plasmid and repair template incorporate the desired allele and clones without the  
539 desired allele are easily identified by screening for maintained expression of the cassette selectable  
540 marker. 2) gRNAs do not need to be designed and tested for each region due to the use of a common  
541 gRNA. 3) Regions without a nearby PAM site can be engineered because the gRNAs target  
542 integrated cassettes rather than the genomic region directly. 4) Larger regions, including those that  
543 contain essential genes can be engineered by flanking the region with two cassettes and using a  
544 single gRNA to cut and swap both cassettes and the intervening region. 5) Our gRNAs can be  
545 directly used to engineer existing strains that already contain cassettes e.g., strains in the *S.*  
546 *cerevisiae* deletion and GFP collections [72,73].

547 While we successfully used GFP-tagged protein abundance as phenotypic readouts amenable to  
548 high-throughput measurement, the hotspots we dissected had been identified via their effects on  
549 mRNA levels. The effects of the locus on the mRNA and protein of the gene used for phenotyping  
550 cannot always assumed to be consistent [22,37]. Further, fine-mapping using the expression of a  
551 single focal gene can only detect variants that influence this focal gene. Additional variants in the  
552 same region that specifically affect other genes would be missed. Indeed, while our RNA-Seq  
553 results were consistent with single causal variants at *OAF1* and *OLE1*, they suggested the presence  
554 of a second causal variant close to *RGT2*, which acts on genes involved in purine metabolism.  
555 Evidently, even such narrowly mapped hotspot loci as those we dissected here can be due to  
556 multiple causal variants with distinct effects but in close proximity to each other, as has been  
557 observed for QTLs for other traits in yeast [74,75].

558 A key result from this work is that the three causal variants we identified are strikingly different  
559 from each other. First, the variants include two coding missense variants (in *RGT2* and *OAF1*),  
560 along with the *cis*-acting noncoding FAR variant at *OLE1*. In yeast, 10 additional natural variants  
561 have been experimentally demonstrated to affect gene expression in *trans*, and there are 5  
562 additional hotspots for which the gene but not the causal variant is known (S7 Table ,

563 [18,20,23,30,31,34,38–41], see also [76]) Coding variation underlies at least 13 of these 18 cases,  
564 including missense, frameshift and transposon insertion variants. In species other than yeast,  
565 information about causal *trans* eQTL variants remains extremely limited [77–80]. In human  
566 genetics, searches for *trans* eQTLs often assume a model in which noncoding variants alter the  
567 expression of a regulator gene in *cis*, which in turn alters the expression of other genes in *trans*  
568 [81–85]. The FAR variant at *OLE1* discovered here is an example of such a mechanism. However,  
569 the predominance of causal coding variants in yeast suggests that *trans* eQTLs caused by coding  
570 variants may also exist in other species.

571 Second, the genes affected by the three variants encode different types of proteins: a glucose sensor  
572 (Rgt2), a transcription factor (Oaf1), and the essential enzyme Ole1. While genes encoding  
573 transcription factors are enriched in hotspot regions [12], hotspots clearly also arise from other  
574 gene classes (S7 Table). Among these, enzymes are a particularly interesting group. Because most  
575 enzymes do not directly regulate gene expression, metabolic changes caused by differential  
576 enzyme activity or expression must trigger *trans* changes in gene expression indirectly [86,87].  
577 The FAR variant at *OLE1* illustrates the indirect mechanisms that could underlie such indirect  
578 *trans* effects. Its RM allele reduced Ole1 expression and increased saturated NEFAs. Higher lipid  
579 saturation decreases membrane fluidity [88–90] which is sensed by membrane-bound dimers of  
580 Mga2 or Spt23 [88,91–93]. In our data, the FAR RM allele increased *MGA2* expression in *trans*.  
581 Apparently, this noncoding variant perturbs mechanisms involved in membrane homeostasis,  
582 which may ultimately alter gene expression via the transcriptional regulator *MGA2*.

583 The *trans* effects of the FAR variant were caused by a decrease in Ole1 levels of only about 15%  
584 (Fig 5B & 6). Such sensitivity to small expression changes may be unusual among genes. While  
585 the BY and RM strains carry thousands of local eQTLs affecting at least half of the genes in the  
586 genome, most of these local eQTLs do not result in detectable expression changes at other genes  
587 in *trans* [12]. Little is known about whether, when, and how small expression changes at one gene  
588 influence other genes in *trans*, and how some of these changes go on to influence the organism.  
589 Pioneering studies have shown that even relatively small reductions in the expression of the  
590 enzyme genes *TDH3* [94] and *LCB2* [95] can reduce fitness, and that the relationship between  
591 gene expression and fitness is specific to each gene [96], the environment [96], and the strain  
592 background [95]. Future work will explore the causal relationships among fitness and gene  
593 expression changes in *trans*.

594 Finally, the three causal variants we discovered also differed in their population genetic  
595 characteristics. The *OAF1(S63L)* variant is rare, while the *RGT2* and *OLE1* variants are found in  
596 many isolates. These two common variants differ in the degree of evolutionary conservation of  
597 their site, with poor conservation at *RGT2(V539I)* and high conservation at the noncoding FAR  
598 variant. At least in the case of *RGT2*, simple evolutionary conservation alone would not have been  
599 sufficient to predict the causal variant.

600 At all three variants, the derived alleles affected *trans* gene expression in the same direction as loss  
601 of function or reduced function alleles. While this suggests that the derived alleles are detrimental,  
602 the high frequency in the population of the *RGT2* and *OLE1* alleles argues against strong negative  
603 fitness consequences. While these two variants could potentially be beneficial in some  
604 backgrounds or conditions, they could also be sufficiently mildly deleterious to have drifted to  
605 high frequency, as has been proposed to be the case for many *trans*-acting polymorphisms [97,98].  
606 Indeed, none of the three variants resulted in consistent growth differences in both backgrounds in  
607 our culture medium (Table 1), suggesting that any fitness effects they may have are minor or occur  
608 in other environments. For example, at *RGT2*, the effect of the V539I variant on *HXT1* expression  
609 was reduced dramatically simply by altering the amount of glucose in the medium, suggesting that  
610 the long-term evolutionary consequences of this variant could be highly dependent on the  
611 environment.

612 With the arrival of population-scale genome sequencing [99], the functional interpretation of  
613 individual DNA variants has become a major goal of genetics, and numerous experimental and  
614 computational approaches aiming to predict phenotypic consequences of variants have been  
615 developed [53,100–107]. The diverse nature of variants that cause *trans*-eQTLs revealed here will  
616 make prediction of *trans* effects challenging. More data on the effects of variants on gene  
617 expression in *trans* will be important to understand *trans*-regulatory variation, both from high  
618 throughput approaches [108–114], and focused dissection of individual hotspots.

619 **Materials and methods**

620 **Strains, Plasmids, Primers and Media**

621 Experiments were performed in haploid *S. cerevisiae* strains derived from S288C (BY4741  
622 (MAT<sub>a</sub>, his3Δ1 leu2Δ0 met15Δ0 ura3Δ0), referred to as “BY” in the text) and RM-11a, (RM  
623 HO(BY) (MAT<sub>a</sub>, his3Δ1::CloNAT, leu2Δ0, ura3Δ0 HO(BY allele) AMN1(BY allele), referred to  
624 as “RM”). All strains used in this study can be found in S8 Table. The HO(BY) allele was  
625 introduced into this RM strain by replacing the hphMX cassette at HO with the BY allele in  
626 YLK2442 (a gift from L. Kruglyak) by CRISPR-Swap. Importantly, the CloNAT resistance gene  
627 at the *HIS3* locus in RM HO(BY) is not recognized by the gCASS5a. All plasmids used in this  
628 study are in S9 Table. All primers/oligonucleotides are in S10 Table.

629 We used the following media (recipes are for 1L):

630 YNB+2% Glu +all (6.7 g yeast nitrogen base with ammonium sulfate and without amino acids, 20  
631 g glucose, 50 mg histidine, 100 mg leucine, 50 mg methionine, 200 mg uracil and sterilized by  
632 filtration)

633 YNB+2% Glu -Leu (YNB+2% Glu+all (without leucine)

634 YPD (10 g yeast extract, 20 g peptone, 20 g glucose)

635 SDC-Leu (1.66 g SC -His -Leu -Ura, 50 mg histidine, 200 mg uracil, 20 g glucose)

636 SDC-His (1.66 g SC -His -Leu -Ura, 100 mg leucine, 200 mg uracil, 20 g glucose)

637 LB (10 g tryptone, 10 g NaCl, 5 g yeast extract)

638 Media for selection of resistance gene expression was supplemented at the following  
639 concentrations: ampicillin (100  $\mu$ g/ml), nourseothricin sulfate (100  $\mu$ g/ml), G418 sulfate (200  
640  $\mu$ g/ml), hygromycin B (300  $\mu$ g/ml). For solid media, 20 g/L agar was added prior to autoclaving.  
641 Yeast were grown at 30°C. Bacteria were grown at 37°C.

642

643 **Plasmid construction**

644 To construct the CRISPR-Swap plasmids we annealed oligos OFA0185 and OFA0186 for  
645 gCASS5a (pFA0055) and OFA0552 and OFA0553 for gGFP (pFA0057), and ligated them into  
646 the BclI and SwaI sites of pML107, a gift of John Wyrick (Addgene #67639) as described in [45].

647 We are depositing pFA0055 and pFA0057 to Addgene under #131774 and #131784, respectively.

648 The yeVenus reporter plasmids were created by PCR fusion of the *OLE1* (-1 to -936) or *SDS23* (-  
649 1 to -1090) promoter fragment with the open reading frame of yeVenus, a gift of Kurt Thorn  
650 (Addgene plasmid #8714) [115]. To create plasmids pRS415-p*OLE1*(BY)-yeVenus and pRS415-  
651 p*OLE1*(RM)-yeVenus, the *OLE1* promoter and yeVenus PCR fragments were digested with  
652 HindIII and BglII and ligated into pRS415 [116] digested with HindIII and BamHI. To create  
653 pRS415-p*OLE1*(BY\_FAR\_RM)-yeVenus and pRS415-p*OLE1*(RM\_FAR\_BY)-yeVenus the  
654 *OLE1* promoter PCR fragment was digested with HindIII and PstI and ligated into the same sites  
655 of pRS415-*OLE1*(BY)-yeVenus\_1. To create pRS415-*SDS23*(BY)pVenus, the *SDS23* promoter  
656 and yeVenus PCR fragment was digested with SalI and NdeI and cloned into the same sites of  
657 pRS415-p*OLE1*(BY)-yeVenus\_1. For details on the creation of the PCR fusions see S11 Table.

658

659 pRS415-*OLE1*(BY) was created by ligating the *OLE1*(BY) gene (-936 to +373) after PCR  
660 amplification and digestion with HindIII (native in *OLE1*) and BamHI (on OFA0641 primer) into  
661 the same sites of pRS415. pRS415-*SDS23*(BY) was created by ligating the *SDS23*(BY) gene (-  
662 1033, +4730) after PCR amplification and digestion with BamHI and SacI into the same sites of  
663 pRS415. pRS415-*SDS23*-*OLE1*p(BY) was created by ligating the 1009-bp intergenic region  
664 between *SDS23* and *OLE1* after PCR amplification and digestion with BamHI and HindIII into  
665 the same sites of pRS415.

666

## 667 **Tagging genes and cassette insertion**

668 Insertions of cassettes for genome modification were performed using a standard PCR-based  
669 one-step method [50]. Selection markers used were HIS3MX6, which allows growth of *his3*-  
670 mutants without exogenous histidine, KanMX4, which allows growth with G418, natMX6,  
671 which allows growth with nourseothricin sulfate/CloNAT and hphMX4 or hphNT1, which  
672 allows growth with hygromycin B. For C-terminal tagging of *HXT1*, we used the GFP-

673 HIS3MX6 cassette for tagging of *HXT1*, and the mCherry-hphNT1 cassette, a gift of Jiří Hašek  
674 (Addgene plasmid #74635) [117] for tagging of *OLE1*. For the first step of CRISPR-Swap, we  
675 used KanMX4 and hphMX cassettes for gene deletion or for cassette insertion without deletion.  
676 After selection for these markers, the transformants were single colony purified and insertion  
677 of the cassette in the correct location and absence of the wild-type allele were verified by PCR.

678

### 679 **Construction of repair templates for CRISPR-Swap**

680 Repair templates were PCR amplified from BY and RM genomic DNA with primers designed to  
681 create products with termini homologous (ranging from 84 – 338 bp) to the region flanking the  
682 targeted cassette and, when possible, to be free of BY/RM sequence differences. To create hybrid  
683 BY and RM repair templates, we used PCR SOEing techniques [118]. See S11 Table for details  
684 on construction of each template.

685

### 686 **CRISPR-Swap**

687 Strains were transformed with the gCASS5a or gGFP plasmid and a PCR-generated repair  
688 template using a standard lithium acetate procedure [119]. For each transformation, we used 25 ml  
689 of cells at  $OD_{600}= 0.4-0.8$ . To prepare 50 ml of cells for transformation, the cells were pelleted by  
690 centrifugation at 3,000 g for 3 min, the supernatant removed and the cells were resuspended in 1  
691 ml water and transferred to a 1.7 ml microfuge tube. The cells were pelleted at 2,500 g for 2 min,  
692 the supernatant removed, and the cells were resuspended in 1 ml of Solution 1 (0.1M LiAc, 1X TE  
693 buffer). The cells were pelleted once again, supernatant removed, and then resuspended in 200  $\mu$ l  
694 of Solution 1. For each transformation, ~125  $\mu$ l of the cell mixture was transferred to a 1.7 ml  
695 microfuge tube containing 100 ng of the guide RNA plasmid, 1000 ng of PCR-generated repair  
696 template and 5  $\mu$ l (10  $\mu$ g/ $\mu$ l) of salmon sperm carrier DNA (Sigma #D7656) and the tube was  
697 incubated on a turning wheel at 30°C for 30 min. After which, 700  $\mu$ l of Solution 2 (0.1M LiAc,  
698 1X TE and 40% PEG 3350) was added and the mixture was returned to the turning wheel and  
699 incubated at 30°C for 30 min. Next, the mixture was incubated at 42°C for 15 min and then 500  
700  $\mu$ l of water was added. To wash the cells prior to plating, the cells were pelleted at 2,500 g for 2  
701 min, the supernatant removed, and the cells were resuspended in 1 ml of water. The cells were

702 pelleted once again at 2,500 g for 2 min, the supernatant removed, and the cells resuspended in  
703 200  $\mu$ l of water, plated onto two SDC-Leu plates, and incubated at 30°C for 3 – 4 days. The median  
704 number of colonies growing on SDC-Leu after single-cut CRISPR-Swap was 38 for BY and 3 for  
705 RM strains. After double-cut CRISPR-Swap there were ~50% fewer transformants in each  
706 background. The resultant leucine prototrophic colonies were single-colony purified on SDC-Leu  
707 plates and then assayed for loss of the selectable marker cassette by identifying strains that could  
708 no longer grow on YPD with G418, or, for *OLE1* allele exchanges, YPD with G418 and/or YPD  
709 with hygromycin. We did not cure the strains of the CRISPR-Swap plasmid with the exception of  
710 the strains used for RNA sequencing and the RM HO(BY) strain YFA0254. In our experience, the  
711 plasmid is rapidly lost and therefore was likely not present during phenotyping of the strains. To  
712 cure the strains of the plasmid, the strains were single-colony streaked and then replica plated to  
713 SC-Leu to identify leucine auxotrophic colonies. We preserved a minimum of three independently  
714 derived strains for each allele swap in glycerol (15% final concentration) stored at -80°C.

715

## 716 **Verification of allele exchange**

717 We performed colony PCR to verify the absence of the selectable marker cassette(s) and presence  
718 of the desired allele. Further verification of variant incorporation was in some cases performed by  
719 sequencing or by restriction enzyme digestion. To verify variants by enzyme digestion, we  
720 screened for the presence of an SspI site created by the *OAF1* L63S BY allele and an NcoI site  
721 created by the *OLE1* L304M RM allele. We did not always verify the allele exchange since we  
722 found that 100% of the colonies that no longer expressed the selectable marker had the desired  
723 allele. Special cases of allele exchange verification are described below.

724 The *RGT2* repair templates in some allele swaps contained a single indel variant within the 5'  
725 homologous flanking region. In these strains, the variant was sequenced and only strains with the  
726 desired variant were preserved when possible. In other cases, the mismatched variant is indicated  
727 in Fig 2 and S8 Table. We found this variant to have no effect on expression of Hxt1-GFP.

728 The BY FAA4-GFP *OLE1*(L304M) strains were created using single-cut CRISPR-Swap of the  
729 KanMX cassette in BY FAA4-GFP DAmP(*OLE1*) (YFA0547) and a repair template made from  
730 BY genomic DNA with OFA0519, which carries the RM variant at L304M, and OFA0120.  
731 Because the site of homologous recombination can initiate anywhere along the *OLE1* gene present

732 in the genome, the L304M variant was verified by restriction digestion and sequencing and 4 of  
733 10 allele swaps successfully incorporated the RM variant at L304M.

734 When performing double-cut CRISPR-Swap at the *OLE1* locus, we observed incorporation of  
735 unexpected BY/RM chimeric alleles in 2/36 strains in which we genotyped at least one variant.  
736 We believe this can occur because the *OLE1* repair template is homologous to the sequence  
737 between the two cassettes, allowing recombination to occur between the repair template and the  
738 intervening sequence.

739

#### 740 **Phenotyping of engineered strains**

741 Precultures were inoculated with cells from strains freshly growing on YPD plates or from glycerol  
742 stocks and grown overnight in 800 – 1000  $\mu$ l of YNB+2% Glu+all medium in a 2-ml deep-96-  
743 well-plate on an Eppendorf Mixmate shaker set at 1100 rpm at 30°C. The precultures were diluted  
744 to an  $OD_{600}=0.05$  in 100  $\mu$ l of the same medium in a 96-well flat bottom plate (Costar) and the  
745 plates were sealed with a Breathe Easy membrane (Diversified Biotech). The strains were  
746 phenotyped in a BioTek Synergy H1 (BioTek Instruments) plate reader at 30°C with readings  
747 taken every 15 min for 97 cycles with 10 sec of orbital shaking between reads and 11 – 13 min  
748 between cycles. Cell growth was characterized using absorbance readings at 600 nm and protein  
749 expression was measured using fluorescence readings taken from the bottom of the plate with the  
750 following parameters: GFP (excitation 488, emission 520 nm) and yeVenus (excitation 502,  
751 emission 532 nm) with an average of 10 reads per well and gain set on extended; and mCherry  
752 (excitation 588 nm, emission 620 nm) with an average of 50 reads per well and gain set at 150.

753 All plate reader measurements are available at our code repository at  
754 <https://github.com/frankwalbert/threeHotspots>.

755

#### 756 **Growth of *RGT2* strains in different glucose concentrations**

757 *HXT1*-GFP tagged strains, BY (YFA0276-8), BY RGT2(V539I) (YFA0489-91), RM (YFA0279-  
758 81) and RM RGT2(I539V) (YFA0492-95) were precultured overnight in 1 ml of YNB+all with  
759 the indicated glucose concentration (1%-12% glucose w/vol.) The cultures were diluted in 100  $\mu$ l  
760 of the same media and phenotyped as described above. We removed one strain (YFA0275, a BY

761 wild type strain present on one plate) from the analyses because it showed highly unusual *HXT1*-  
762 GFP expression at high glucose.

763

764 **yeVenus reporter expression**

765 Strains BY (YFA0993), RM (YFA0254), or BY OAF1(L63S) (YFA0907) were transformed with  
766 pRS415-based plasmids containing *OLE1* / *SDS23* intergenic fragments driving expression of the  
767 yeVenus reporter. Phenotyping was performed as described above in YNB+2% Glu -Leu to  
768 maintain the plasmids. Precultures were inoculated with transformants that were single colony  
769 purified on SDC-Leu plates or using pools of transformants (~5-10 colonies) taken directly from  
770 the SDC-Leu transformation plates and grown overnight, diluted, and phenotyped as described  
771 above.

772

773 **Modulation of *OLE1* expression using *Z<sub>3</sub>EV***

774 The BY *FAA4-GFP* strain expressing the estradiol responsive transcription activator was created  
775 by inserting p*ACT1*-*Z<sub>3</sub>EV*-NATMX [63] at the *HO* locus, S11 Table for more details. The *OLE1*  
776 gene was then modified to have the *Z<sub>3</sub>EV* responsive promoter cassette (KANMX-p*Z<sub>3</sub>EV* and a  
777 C-terminal fusion with mCherry-hphNT1. Cells of BY *FAA4-GFP* *OLE1*-mCherry(YFA1105),  
778 BY *FAA4-GFP* *OLE1*(FAR\_RM)-mCherry(YFA1140) and BY *HO*::p*ACT1*\_*Z<sub>3</sub>EV* *FAA4-GFP*  
779 *Z<sub>3</sub>EVpOLE1*-mCherry (YFA1110; glycerol stock prepared from a culture grown in 8 nM  
780 estradiol) were precultured overnight in 250  $\mu$ l of YNB+2% Glu+all with 4, 5, 6, 8, 10, 15, 20, 30  
781 or 40 nM of estradiol (Sigma E1024: 10  $\mu$ M stock solution in ethanol), diluted in 100  $\mu$ l of the  
782 same media, and phenotyped as described above.

783

784 **Extraction and sequencing of mRNA**

785 Strains BY(YFA1130), BY RGT2 back to WT(YFA1131), BY OAF1(L63S) (YFA1132), BY  
786 *OLE1*(FAR\_RM) (YFA1133) and BY RGT2(V539I) (YFA1134) were precultured (7 precultures  
787 of each strain) in 1 ml of YNB+2% Glu+all as described above. After ~18 hours of growth, the  
788 precultures were diluted to OD<sub>600</sub>=0.05 in 1 ml of the same media. After ~7 hours of growth, the  
789 optical density of the cultures was measured in the plate reader and growth was continued until an

790 average plate OD<sub>600</sub> = 0.37, at which time the plate was centrifuged for 3 min at 2,100 g, the  
791 supernatant removed, and each cell pellet was resuspended in 1 ml of H<sub>2</sub>O and transferred to a 1.7  
792 ml microfuge tube. The tubes were centrifuged for 2 min at 16,000g, the supernatant removed, and  
793 the cell pellets were immediately frozen by immersion of the tube in liquid nitrogen and stored at  
794 -80°C.

795 Five cell pellets from each strain were chosen for RNA isolation so that the average OD<sub>600</sub> within  
796 and between strains were as uniform as possible, with an average OD<sub>600</sub> = 0.37 (range of 0.34 to  
797 0.40). Total RNA was isolated from cell pellets in 5 batches (each batch contained one of each of  
798 the 5 strains) using the ZR Fungal/Bacterial RNA mini-prep kit including the DNase I on-column  
799 digestion step (Zymo Research). Each cell pellet was resuspended in lysis buffer and transferred  
800 to screw-capped tubes containing glass beads and the cells were broken open using a mini-  
801 beadbeater (Biospec Products) in 5 cycles of 2 min bead beating followed by 2 min at -80°C. The  
802 total RNA was eluted in 50 µl of DNase/RNase free water and the RNA Integrity and  
803 concentration was measured using an Agilent 2200 Tape Station. RINe scores ranged from 9.8 –  
804 10, with an average RNA concentration of 137 ng/µl.

805 Poly-A RNA was extracted from 550 ng of total RNA using NEBNext Poly(A) mRNA Magnetic  
806 Isolation Module (NEB) and used as input into the NEB Ultra II Directional RNA library kit for  
807 Illumina (NEB E7760) in two batches. NEBNext Multiplex Oligos for Illumina (Dual Index  
808 Primers Set1) were used to amplify and barcode the libraries using the following cycling  
809 conditions: Initial Denaturation at 98°C for 30 s and 10 cycles of: 98°C for 10 s and 65°C for 75  
810 s, followed by a 65°C extension for 5 min.

811 The amplified DNA was quantified using Qubit DNA HS. Sample concentrations ranged from 47  
812 – 102 ng/µl. An equal concentration of each of the 25 barcoded libraries was pooled and the  
813 average fragment size of the library was 350 bp, as determined using an Agilent High Sensitivity  
814 chip. High-output sequencing of 76-bp single-end reads was performed on an Illumina NextSeq  
815 550 at the University of Minnesota Genomics Core. An average of 14 million reads were obtained  
816 for each sample.

817 Sequencing reads are available at GEO as series GSE134169.

818

819 **Lipid Measurements**

820 Strains BY (YFA0897), RM HO(BY) (YFA0254), BY OAF1(L63S) (YFA0907), BY  
821 OLE1(FAR\_RM) (YFA0914) and BY OLE1(FAR\_RM)OAF1(L63S)(YFA1096) were  
822 precultured (6 precultures of each strain) for ~18 hours in 1 ml of YNB+2% Glu+all and then  
823 diluted in 7 ml of the same media to an  $OD_{600} = 0.002$  in a loosely capped 16 X 150 mm culture  
824 tube and grown at 30°C on a turning wheel until an approximate  $OD_{600} = 0.34$  (measured in plate  
825 reader). Samples were centrifuged for 3 min at 2,100g, the supernatant was removed and the cell  
826 pellets were resuspended in 1 ml of water and transferred to 1.7 ml microfuge tubes. The cells  
827 were pelleted for 2 min at 16,000g, the supernatant removed, and the cell pellets were immediately  
828 frozen by immersion of the tube in liquid nitrogen and stored at -80°C.

829 Cell pellets from each strain were resuspended in 1X PBS and sonicated. Fatty acids and total lipid  
830 composition were measured against a standard curve on a triple quadrupole mass spectrometer  
831 coupled with an Ultra Pressure Liquid Chromatography system (LC/MS) as previously described  
832 [120]. Briefly, the cell pellets were spiked with internal standard prior to extraction with tert-Butyl  
833 Methyl Ether (MTBE). Roughly 25% of the sample was dried down, hydrolyzed, re-extracted and  
834 brought up in running buffer for the analysis of total fatty acid composition. The remaining portion  
835 of the extract was dried down and brought up in running buffer prior to injecting on the LC/MS  
836 for the NEFA measurement. Data acquisition was performed under negative electrospray  
837 ionization condition.

838

839 **Allele frequencies of the variants in the population**

840 The phylogenetic tree used to describe the evolution of the causal variants was obtained from [66]  
841 (personal communication). Briefly, the tree was formed from the analysis of 1,544,489 biallelic  
842 sites across 1,011 *S. cerevisiae* strains using the R package “ape” [121] with the ‘unrooted’ method  
843 to display the tree. For each of the three variants, the matrix of variants from [66] was used to  
844 define which of the 1,011 strains carry the RM allele, the BY allele, both the BY and RM allele,  
845 or another allele. The edges of the tree were colored based on the alleles each strain carries. The  
846 absence of color continuity as seen with *OLE1* and *RGT2* can indicate multiple independent  
847 mutation events, but is more likely to arise from out-crossing events leading to mosaic genomes  
848 [122].

849 Alignments were performed using Clustal Omega ([www.ebi.ac.uk/Tools/msa/clustalo/](http://www.ebi.ac.uk/Tools/msa/clustalo/)) with  
850 default settings. Sequences for alignment were retrieved from the NCBI nucleotide database.  
851 Predictions of variant effect on the function of the Rgt2, Oaf1, Sds23, and Ole1 proteins were  
852 calculated using Provean (Protein Variation Effect Analyzer) (<http://provean.jcvi.org>).

853

#### 854 **Computational and statistical analyses**

855 All analyses described below were conducted in R ([www.r-project.org](http://www.r-project.org)), with individual packages  
856 indicated throughout. Figures were generated using base R and ggplot2 [123]. Analysis code is  
857 available at <https://github.com/frankwalbert/threeHotspots>.

858

#### 859 **Quantification of gene expression from plate reader data**

860 We used the ‘growthcurver’ R package [124] to fit a logistic growth curve to the OD<sub>600</sub> readings  
861 in each well. Every plate had several blank wells that contained medium but no yeast, and we used  
862 these blank wells to correct for the optical density of the medium. We visually confirmed  
863 successful fit of the growth curve for every well, and additionally excluded any wells for which  
864 growthcurver indicated poor model fit. From the fitted growth model, we extracted growth rates  
865 as well as the “inflection point” of the growth curve, i.e. the time point at which the population  
866 reached half its maximum capacity. We chose this time point for our measure of expression  
867 because in practice it closely matches the OD<sub>600</sub> values used to map the hotspots [12], and because  
868 while cultures are still growing exponentially at this time point, they have reached a high enough  
869 density to allow accurate quantification of fluorescence.

870 To obtain expression values for downstream analyses, we subtracted the mean OD<sub>600</sub> and mean  
871 fluorescence of the blank wells included on each plate from all other wells on the plate. We  
872 calculated the mean of three background-subtracted time points centered on the inflection point  
873 (Fig 1C) for OD<sub>600</sub> and fluorescence. Downstream analyses of gene expression used the ratio of  
874 this mean fluorescence divided by the mean OD<sub>600</sub>.

875 Prior to statistical analysis, we log<sub>2</sub>-transformed these fluorescence ratios. Every plate that carried  
876 strains with the BY and RM backgrounds also carried untagged wild type control strains without  
877 any fluorescent markers. We subtracted the average log<sub>2</sub>(fluorescence ratio) values from these

878 untagged strains from those of the tagged strains. Thus, the fluorescent phenotypes used in  
879 statistical analyses and displayed in the figures are in units of  $\log_2$ -fold change compared to  
880 untagged strains with matched genetic background.

881

## 882 **Statistical analyses of plate reader data**

883 For fine-mapping, we used pairwise comparisons of genotypes to determine whether the  
884 expression associated with a given edited allele differed significantly from the wild type or other  
885 alleles. These pairwise tests were computed using mixed linear models whose random effect terms  
886 depended on the structure of the data available for each comparison. Specifically, two random  
887 terms were included where appropriate:

888 **Plate identity.** As fine-mapping progressed, most genotypes were measured on several plate runs,  
889 usually along with different sets of other genotypes. This resulted in a complex data structure in  
890 which genotypes were sometimes but not always included on the same plates, run over a span of  
891 several months. To account for this structure, the model included plate identity as a random term.  
892 To ensure that plate effects were properly accounted for in both genotypes in a given pairwise  
893 comparison, each comparison was computed using only data from plates that carried both  
894 genotypes under consideration. For example, while wildtype strains were run on multiple plates, a  
895 given edited strain may only have been present on one of these plates. In this scenario, only this  
896 one plate would be used in the statistical comparison. Note that data in figures in the paper that  
897 display plate reader data from multiple plates were not corrected for plate effects. We chose to not  
898 correct for plate effects in the plots because we wished to present a raw view of the data, and  
899 because there is no good way to apply a common visual correction for plate identity when different  
900 genotype comparisons require different plate corrections, depending on which genotypes were  
901 present on each plate. In the figures, plate identity is indicated with different symbols (dots,  
902 squares, triangles, etc.).

903 **Clone identity.** During strain engineering, we created at least three independent clones of each  
904 strain. Clone identity was included in the model as a random effect to control for any systematic  
905 differences among these clones. In the figures, we visually grouped data from different wells for a  
906 clone by connecting these wells with a line. For the yeVenus reporter experiments, we collected  
907 data from individual transformed colonies as well as from small transformant pools that each

908 contained (and effectively averaged) multiple colonies. For statistical analyses, we treated each  
909 small transformant pool as if it were a colony.

910 In the equations below, we denote random effects in parentheses. For each genotype, we used the  
911 “lmer” function in the lme4 package [125] to fit a model of the phenotype  $y$  with the above random  
912 effect terms as appropriate:

913  $H0: y = (\text{plate}) + (\text{clone}) + \varepsilon$

914 where  $\varepsilon$  is the residual error. We fit a second model that includes a fixed effect term for genotype  
915 identity:

916  $H1: y = (\text{plate}) + (\text{clone}) + \text{genotype} + \varepsilon$

917 We tested for significance of the genotype term using ANOVA comparing  $H0$  and  $H1$ . Note that  
918 for a few comparisons in which only a single clone was run in replicate on a single plate, we did  
919 not include random effects terms. We fit these models using the “lm” function.

920 P-values in plate reader analyses during fine mapping were not corrected for multiple testing.

921

## 922 **Tests for non-additive genetic interactions**

923 To test for non-additive interactions of a given allele (i.e., the BY or RM allele at a given causal  
924 variant) with the strain background (BY or RM), we fit a model with a fixed effect term for strain  
925 background, in addition to a term for the allele at the variant of interest:

926  $H0: y = (\text{plate}) + (\text{clone}) + \text{strain} + \text{allele} + \varepsilon$

927 and a second model that adds an interaction term between allele and strain background:

928  $H1: y = (\text{plate}) + (\text{clone}) + \text{strain} + \text{allele} + \text{strain:allele} + \varepsilon$

929 We used ANOVA to test if the inclusion of the  $\text{strain:allele}$  interaction term in  $H1$  significantly  
930 improved model fit. These interaction tests only considered plates that contained both alleles for  
931 the given variant in both strain backgrounds. We used the same models to test for interactions  
932 between FAR alleles and *OAF1* alleles by replacing the “RM” factor level in *strain* with “BY  
933 (OAF1-RM)”.

934 To compare the *OAF1/OLE1* allele interaction to that observed earlier in eQTL data (Source Data  
935 14 in [12]), we obtained expression values (Source Data 1 from [12]) and used a linear model to  
936 regress out effects of collection batch and OD<sub>600</sub> for these data (Source Data 2 from [12]). We then  
937 used genotypes (Source Data 3 from [12]) at the marker positions corresponding to the two  
938 interacting loci at *OAF1* and *OLE1* to divide the segregants in [12] into four two-locus genotype  
939 classes and plot their *FAA4* mRNA levels in Fig 7A.

940

#### 941 **Dependence of the *RGT2*(V539I) effect on glucose concentration**

942 To test if the effect of the causal variant in *RGT2* depended on glucose concentration in the  
943 medium, we extended our modeling framework to include *glucose* ( $\log_2(\text{glucose concentration})$ )  
944 as a numeric covariate. We fit a model that included all possible pairwise interactions between  
945 strain, allele, and glucose:

946  $H1: y = (\text{plate}) + (\text{clone}) + \text{strain} + \text{allele} + \text{glucose} + \text{strain:allele} + \text{strain:glucose} +$   
947  $\text{allele:glucose} + \varepsilon$

948 and compared this model to simpler models from which we dropped the respective interaction term  
949 of interest. For example, to test for the interaction between glucose and the allele effect:

950  $H0: y = (\text{plate}) + (\text{clone}) + \text{strain} + \text{allele} + \text{glucose} + \text{strain:allele} + \text{strain:glucose} + \varepsilon$

951 We computed p-values comparing these models using ANOVA.

952

#### 953 **RNASeq data handling**

954 We used trimmomatic [126] version 0.38 to trim Illumina adapters, filter out reads shorter than 36  
955 bp, trim bases with a quality score of less than 3 from the start and end of each molecule, and  
956 perform sliding window trimming to remove bases with an average quality of less than 15 in a  
957 window of four bases. This filtering retained  $\geq 97\%$  of reads. We used kallisto [127] to pseudoalign  
958 these trimmed and filtered reads to the *S. cerevisiae* transcriptome obtained from Ensembl [128]  
959 build 93 based on genome version sacCer3 [129]. Following recommendations in [130], we used  
960 FastQC [131] and RSeQC [132] to examine the quality of our 25 samples and found them to all

961 be of high quality and, importantly, highly similar to each other. We retained all 25 samples for  
962 downstream analysis.

963 As a measure of gene expression, we used “estimated counts” in the kallisto output for each gene  
964 in each sample. To exclude genes with poor alignment characteristics, we used RSeQC to calculate  
965 Transcript Integrity Numbers (TINs) per gene and sample, and also considered “effective gene  
966 length” produced by kallisto. We retained genes in which no sample had a count of zero, no sample  
967 had a TIN of zero, and with effective length larger than zero. This filtering retained 5,400 genes  
968 (out of 6,713 annotated) for further analysis.

969

## 970 **RNASeq statistical analyses**

971 Statistical analyses were conducted using the DESeq2 R package [133]. During RNA isolation and  
972 sequencing library generation, we had collected a number of covariates and batch identities:  
973 Bioanalyzer-based RNA Integrity Number (RIN), Bioanalyzer-based RNA concentration, Qubit-  
974 based RNA concentration, OD<sub>600</sub> of the culture at time of flash freezing, as well as batch for cell  
975 harvest, RNA isolation, and library generation. Samples from our 5 genotypes had been distributed  
976 equally among these three batches. We examined the influence of these technical covariates by  
977 comparing them to principal components computed on variance-stabilized data [133] and found  
978 that the three batches (in particular cell harvest) appeared to influence the results. We thus included  
979 these three batches as covariates in all further analyses. We used surrogate variable analysis (SVA)  
980 [134] to further account for unexplained technical variation and included two SVs in our statistical  
981 model. While choices about which specific technical covariates and SVs to include in the model  
982 did slightly alter the significance tests for individual genes, our main result of positive correlations  
983 between hotspot effects and differential expression was robust to these choices.

984 We fit the DESeq2 model to all 25 samples and conducted pairwise tests for differential expression  
985 between genotypes. Specifically, we compared the edited *OAF1* and *OLE1* alleles to a BY  
986 wildtype strain (YFA1130) engineered by CRISPR-Swap with gGFP to remove the GFP tag from  
987 *FAA4*. We compared the edited *RGT2* variant to a BY wild type strain (YFA1131) engineered by  
988 CRISPR-Swap with gCASS5a to replace *rgt2Δ::kanMX6* with the *RGT2* BY allele. The main text  
989 describes differential expression results based on either nominal p-values ( $p < 0.05$ ), or based on

990 a multiple-testing corrected threshold computed via false discovery rate estimation using the  
991 Benjamini-Hochberg method [135] as reported by DESeq2.

992 To compare differential expression to hotspot effects, we used  $\log_2$ -fold changes estimated by  
993 DESeq2 and hotspot effects that had been estimated by fitting a lasso model to all expressed genes  
994 and all 102 hotspots, as described in [12]. These hotspot effects were obtained from Source Data  
995 9 in [12]. We used nonparametric Spearman rank correlation to compare differential expression  
996 with the hotspot lasso coefficients. We excluded genes with a hotspot effect of zero. While  
997 inclusion of these genes slightly degraded the magnitude of the correlations between hotspot  
998 effects and differential expression, all correlations remained significant and positive.

999 Gene ontology enrichment analysis for genes with strong hotspot effects but no differential  
1000 expression was conducted using the “Gene Ontology Term Finder” tool on SGD [136]. As the  
1001 background set, we used all genes present in both the hotspot effect matrix and our RNASeq data.  
1002 As the test set, we used genes with an absolute hotspot effect of at least 0.3 and a differential  
1003 expression p-value larger than 0.3.

1004

## 1005 **Statistical analyses of lipid data**

1006 To correct for possible technical confounders from lipid composition and NEFAs, we used a linear  
1007 model to regress out effects of acquisition order and sample grouping. For NEFAs, we also  
1008 regressed out total protein, which had been measured from the same samples. The residuals from  
1009 these regression were used in the statistical analyses below. To obtain total saturated, unsaturated,  
1010 C18, and C16 measures, we summed the measures for the respective individual lipid species in  
1011 these groups.

1012 To analyze the effects of the *OAF1* and *OLE1* alleles in the BY background, we jointly considered  
1013 the measures from the four genotypes (BY, BY(*OAF1-L63S*), BY(FAR-RM), and BY with both  
1014 RM alleles) by fitting a linear model to each lipid compound  $y$  that models the effects of the *OAF1*  
1015 and the FAR allele at *OLE1*:

$$1016 \quad y = OAF1 + OLE1 + OAF1:OLE1 + \varepsilon$$

1017 where  $\varepsilon$  is the residual error. We analyzed this model using ANOVA to test for main effects of  
1018 each allele as well as for the interaction term. P-values were not corrected for multiple testing.

1019 The BY and RM backgrounds we compared using T-tests.

1020 **Acknowledgements**

1021

1022 We thank Mahlon Collins, Randi A., Krisna Van Dyke, Joshua Bloom, and Meru Sadhu for  
1023 critical reading and comments on the manuscript. We thank Leonid Kruglyak, David  
1024 Kirkpatrick, Melissa Gardner, and Scott McIsaac for yeast strains and plasmids, and Anne  
1025 Friedrich for help with the 1,011 yeast isolate genome data.

1026 **References**

1027

1028 1. Albert FW, Kruglyak L. The role of regulatory variation in complex traits and disease.  
1029 *Nature Reviews Genetics*. 2015;16: 197–212.

1030 2. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, et al. Systematic  
1031 Localization of Common Disease-Associated Variation in Regulatory DNA. *Science*. 2012;337:  
1032 1190–1195.

1033 3. Liu H, Luo X, Niu L, Xiao Y, Chen L, Liu J, et al. Distant eQTLs and Non-coding  
1034 Sequences Play Critical Roles in Regulating Gene Expression and Quantitative Trait Variation in  
1035 Maize. *Molecular Plant*. 2017;10: 414–426. doi:10.1016/j.molp.2016.06.016

1036 4. Wallace JG, Bradbury PJ, Zhang N, Gibon Y, Stitt M, Buckler ES. Association Mapping  
1037 across Numerous Traits Reveals Patterns of Functional Variation in Maize. *PLOS Genetics*.  
1038 2014;10: e1004845. doi:10.1371/journal.pgen.1004845

1039 5. Wittkopp PJ, Kalay G. Cis-regulatory elements: molecular mechanisms and evolutionary  
1040 processes underlying divergence. *Nature Reviews Genetics*. 2012;13: 59–69.

1041 6. Kita R, Venkataram S, Zhou Y, Fraser HB. High-resolution mapping of cis-regulatory  
1042 variation in budding yeast. *Proceedings of the National Academy of Sciences*. 2017;114:  
1043 E10736–E10744.

1044 7. Tewhey R, Kotliar D, Park DS, Liu B, Winnicki S, Reilly SK, et al. Direct Identification  
1045 of Hundreds of Expression-Modulating Variants using a Multiplexed Reporter Assay. *Cell*.  
1046 2016;165: 1519–1529.

1047 8. Arensbergen J van, Pagie L, FitzPatrick VD, Haas M de, Baltissen MP, Comoglio F, et  
1048 al. High-throughput identification of human SNPs affecting regulatory element activity. *Nat  
1049 Genet*. 2019;51: 1160–1169. doi:10.1038/s41588-019-0455-2

1050 9. Vockley CM, Guo C, Majoros WH, Nodzenski M, Scholtens DM, Hayes MG, et al.  
1051 Massively parallel quantification of the regulatory effects of noncoding genetic variation in a  
1052 human cohort. *Genome Research*. 2015;25: 1206–1214.

1053 10. Chang J, Zhou Y, Hu X, Lam L, Henry C, Green EM, et al. The Molecular Mechanism of  
1054 a Cis-Regulatory Adaptation in Yeast. *PLoS Genetics*. 2013;9: e1003813.

1055 11. Liu X, Li YI, Pritchard JK. Trans Effects on Gene Expression Can Drive Omnipotent  
1056 Inheritance. *Cell*. 2019;177: 1022-1034.e6. doi:10.1016/j.cell.2019.04.014

1057 12. Albert FW, Bloom JS, Siegel J, Day L, Kruglyak L. Genetics of trans-regulatory  
1058 variation in gene expression. *eLife*. 2018;7: e35471.

1059 13. Price AL, Patterson N, Hancks DC, Myers S, Reich D, Cheung VG, et al. Effects of cis  
1060 and trans Genetic Ancestry on Gene Expression in African Americans. *PLOS Genetics*. 2008;4:  
1061 e1000294. doi:10.1371/journal.pgen.1000294

1062 14. Price AL, Helgason A, Thorleifsson G, McCarroll SA, Kong A, Stefansson K. Single-  
1063 tissue and cross-tissue heritability of gene expression via identity-by-descent in related or  
1064 unrelated individuals. *PLoS Genetics*. 2011;7: e1001317.

1065 15. Grundberg E, Grundberg E, Small KS, Small KS, Hedman \AAsa K, Hedman \AAsa K,  
1066 et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. *Nature Genetics*.  
1067 2012;44: 1084–1089.

1068 16. Wright FA, Sullivan PF, Brooks AI, Zou F, Sun W, Xia K, et al. Heritability and  
1069 genomics of gene expression in peripheral blood. *Nature Genetics*. 2014;46: 430–437.

1070 17. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic  
1071 to Omnigenic. *Cell*. 2017;169: 1177–1186.

1072 18. Brem RB, Yvert G, Clinton R, Kruglyak L. Genetic Dissection of Transcriptional  
1073 Regulation in Budding Yeast. *Science*. 2002;296: 752–755.

1074 19. Brem RB, Kruglyak L. The landscape of genetic complexity across 5,700 gene  
1075 expression traits in yeast. *Proceedings of the National Academy of Sciences*. 2005;102: 1572–  
1076 1577.

1077 20. Smith EN, Kruglyak L. Gene–Environment Interaction in Yeast Gene Expression. *PLoS  
1078 Biology*. 2008;6: e83.

1079 21. Albert FW, Muzzey D, Weissman JS, Kruglyak L. Genetic Influences on Translation in  
1080 Yeast. *PLoS Genetics*. 2014;10: e1004692.

1081 22. Albert FW, Treusch S, Shockley AH, Bloom JS, Kruglyak L. Genetics of single-cell  
1082 protein abundance variation in large yeast populations. *Nature*. 2014;506: 494–497.

1083 23. Sudarsanam P, Cohen BA. Single Nucleotide Variants in Transcription Factors Associate  
1084 More Tightly with Phenotype than with Gene Expression. *PLoS Genetics*. 2014;10: e1004325.

1085 24. Lewis JA, Broman AT, Will J, Gasch AP. Genetic Architecture of Ethanol-Responsive  
1086 Transcriptome Variation in *Saccharomyces cerevisiae* Strains. *Genetics*. 2014;198: 369–382.

1087 25. Fraser HB, Moses AM, Schadt EE. Evidence for widespread adaptive evolution of gene  
1088 expression in budding yeast. *Proceedings of the National Academy of Sciences*. 2010;107: 2977–  
1089 2982.

1090 26. Skelly DA, Merrihew GE, Merrihew GE, Riffle M, Riffle M, Connelly CF, et al.  
1091 Integrative phenomics reveals insight into the structure of phenotypic diversity in budding yeast.  
1092 *Genome Research*. 2013;23: 1496–1504.

1093 27. Metzger BPH, Yuan DC, Gruber JD, Duveau F, Wittkopp PJ. Selection on noise  
1094 constrains variation in a eukaryotic promoter. *Nature*. 2015;521: 344–347.  
1095 doi:10.1038/nature14244

1096 28. Gagneur J, Stegle O, Zhu C, Jakob P, Tekkedil MM, Aiyar RS, et al. Genotype-  
1097 Environment Interactions Reveal Causal Pathways That Mediate Genetic Effects on Phenotype.  
1098 *PLoS Genetics*. 2013;9: e1003803.

1099 29. Parts L, Liu Y-C, Tekkedil MM, Steinmetz LM, Caudy AA, Fraser AG, et al. Heritability  
1100 and genetic basis of protein level variation in an outbred population. *Genome Research*. 2014;24:  
1101 1363–1370.

1102 30. Yvert G, Brem RB, Whittle J, Akey JM, Foss E, Smith EN, et al. Trans-acting regulatory  
1103 variation in *Saccharomyces cerevisiae* and the role of transcription factors. *Nature Genetics*.  
1104 2003;35: 57–64.

1105 31. Fehrman S, Bottin-Duplus H, Leonidou A, Mollereau E, Barthelaix A, Wei W, et al.  
1106 Natural sequence variants of yeast environmental sensors confer cell-to-cell expression  
1107 variability. *Molecular Systems Biology*. 2013;9: 695–695.

1108 32. Brem RB, Storey JD, Whittle J, Kruglyak L. Genetic interactions between  
1109 polymorphisms that affect gene expression in yeast. *Nature*. 2005;436: 701–703.

1110 33. Ronald J, Brem RB, Whittle J, Kruglyak L. Local Regulatory Variation in  
1111 *Saccharomyces cerevisiae*. *PLoS Genetics*. 2005;1: e25.

1112 34. Zhu J, Zhang B, Smith EN, Drees B, Brem RB, Kruglyak L, et al. Integrating large-scale  
1113 functional genomic data to dissect the complexity of yeast regulatory networks. *Nature Genetics*.  
1114 2008;40: 854–861.

1115 35. Thompson DA, Cubillos FA. Natural gene expression variation studies in yeast. *Yeast*.  
1116 2017;34: 3–17. doi:10.1002/yea.3210

1117 36. Foss EJ, Radulovic D, Shaffer SA, Ruderfer DM, Ruderfer DM, Bedalov A, et al.  
1118 Genetic basis of proteome variation in yeast. *Nature Genetics*. 2007;39: 1369–1375.

1119 37. Foss EJ, Radulovic D, Shaffer SA, Goodlett DR, Kruglyak L, Bedalov A. Genetic  
1120 Variation Shapes Protein Networks Mainly through Non-transcriptional Mechanisms. *PLoS*  
1121 *Biology*. 2011;9: e1001144.

1122 38. Brown KM, Landry CR, Hartl DL, Cavalieri D. Cascading transcriptional effects of a  
1123 naturally occurring frameshift mutation in *Saccharomyces cerevisiae*. *Molecular Ecology*.  
1124 2008;17: 2985–2997.

1125 39. Kim HS, Huh J, Fay JC. Dissecting the pleiotropic consequences of a quantitative trait  
1126 nucleotide. *FEMS Yeast Res*. 2009;9: 713–722. doi:10.1111/j.1567-1364.2009.00516.x

1127 40. Brion C, Ambroset C, Sanchez I, Legras J-L, Blondin B. Differential adaptation to multi-  
1128 stressed conditions of wine fermentation revealed by variations in yeast regulatory networks.  
1129 *BMC Genomics*. 2013;14: 681. doi:10.1186/1471-2164-14-681

1130 41. Lewis JA, Gasch AP. Natural Variation in the Yeast Glucose-Signaling Network Reveals  
1131 a New Role for the Mig3p Transcription Factor. *G3 - Genes|Genomes|Genetics*. 2012;2: 1607–  
1132 1612.

1133 42. Storici F, Resnick MA. The Delitto Perfetto Approach to In Vivo Site-Directed  
1134 Mutagenesis and Chromosome Rearrangements with Synthetic Oligonucleotides in Yeast.  
1135 *Methods in Enzymology*. Academic Press; 2006. pp. 329–345. doi:10.1016/S0076-  
1136 6879(05)09019-1

1137 43. Alexander WG, Doering DT, Hittinger CT. High-Efficiency Genome Editing and Allele  
1138 Replacement in Prototrophic and Wild Strains of *Saccharomyces*. *Genetics*. 2014;198: 859–866.  
1139 doi:10.1534/genetics.114.170118

1140 44. DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM. Genome engineering in  
1141 *Saccharomyces cerevisiae* using CRISPR-Cas systems. *Nucleic Acids Research*. 2013;41: 4336–  
1142 4343.

1143 45. Laughery MF, Hunter T, Brown A, Hoopes J, Ostbye T, Shumaker T, et al. New vectors  
1144 for simple and streamlined CRISPR–Cas9 genome editing in *Saccharomyces cerevisiae*. *Yeast*.  
1145 2015;32: 711–720. doi:10.1002/yea.3098

1146 46. Akhmetov A, Laurent JM, Gollihar J, Gardner EC, Garge RK, Ellington AD, et al.  
1147 Single-step Precision Genome Editing in Yeast Using CRISPR-Cas9. *Bio-protocol*. 2018;8:  
1148 e2765. doi:10.21769/BioProtoc.2765

1149 47. Wach A, Brachat A, Pöhlmann R, Philippsen P. New heterologous modules for classical  
1150 or PCR-based gene disruptions in *Saccharomyces cerevisiae*. *Yeast*. 1994;10: 1793–1808.  
1151 doi:10.1002/yea.320101310

1152 48. Wach A, Brachat A, Alberti-Segui C, Rebischung C, Philippsen P. Heterologous HIS3  
1153 Marker and GFP Reporter Modules for PCR-Targeting in *Saccharomyces cerevisiae*. *Yeast*.  
1154 1997;13: 1065–1075. doi:10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-  
1155 YEA159>3.0.CO;2-K

1156 49. Goldstein AL, McCusker JH. Three new dominant drug resistance cassettes for gene  
1157 disruption in *Saccharomyces cerevisiae*. *Yeast*. 1999;15: 1541–1553. doi:10.1002/(SICI)1097-  
1158 0061(199910)15:14<1541::AID-YEA476>3.0.CO;2-K

1159 50. Longtine MS, Iii AM, Demarini DJ, Shah NG, Wach A, Brachat A, et al. Additional  
1160 modules for versatile and economical PCR-based gene deletion and modification in  
1161 *Saccharomyces cerevisiae*. *Yeast*. 1998;14: 953–961. doi:10.1002/(SICI)1097-  
1162 0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U

1163 51. Ozcan S, Dover J, Rosenwald AG, Wölfl S, Johnston M. Two glucose transporters in  
1164 *Saccharomyces cerevisiae* are glucose sensors that generate a signal for induction of gene  
1165 expression. *PNAS*. 1996;93: 12428–12432. doi:10.1073/pnas.93.22.12428

1166 52. Özcan S, Johnston M. Function and Regulation of Yeast Hexose Transporters. *Microbiol  
1167 Mol Biol Rev*. 1999;63: 554–569.

1168 53. Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino  
1169 acid substitutions and indels. *Bioinformatics*. 2015;31: 2745–2747.  
1170 doi:10.1093/bioinformatics/btv195

1171 54. Scharff-Poulsen P, Moriya H, Johnston M. Genetic Analysis of Signal Generation by the  
1172 Rgt2 Glucose Sensor of *Saccharomyces cerevisiae*. *G3 (Bethesda)*. 2018;8: 2685–2696.  
1173 doi:10.1534/g3.118.200338

1174 55. Luo Y, Karpichev IV, Kohanski RA, Small GM. Purification, identification, and  
1175 properties of a *Saccharomyces cerevisiae* oleate-activated upstream activating sequence-binding

1176 protein that is involved in the activation of POX1. *J Biol Chem.* 1996;271: 12068–12075.

1177 doi:10.1074/jbc.271.20.12068

1178 56. Rottensteiner H, Kal AJ, Hamilton B, Ruis H, Tabak HF. A heterodimer of the Zn2Cys6

1179 transcription factors Pip2p and Oaf1p controls induction of genes encoding peroxisomal proteins

1180 in *Saccharomyces cerevisiae*. *Eur J Biochem.* 1997;247: 776–783. doi:10.1111/j.1432-

1181 1033.1997.00776.x

1182 57. Karpichev IV, Luo Y, Marians RC, Small GM. A complex containing two transcription

1183 factors regulates peroxisome proliferation and the coordinate induction of beta-oxidation

1184 enzymes in *Saccharomyces cerevisiae*. *Mol Cell Biol.* 1997;17: 69–80. doi:10.1128/mcb.17.1.69

1185 58. Phelps C, Gburcik V, Suslova E, Dudek P, Forafonov F, Bot N, et al. Fungi and animals

1186 may share a common ancestor to nuclear receptors. *Proc Natl Acad Sci U S A.* 2006;103: 7077–

1187 7081. doi:10.1073/pnas.0510080103

1188 59. Stukey JE, McDonough VM, Martin CE. Isolation and characterization of OLE1, a gene

1189 affecting fatty acid desaturation from *Saccharomyces cerevisiae*. *J Biol Chem.* 1989;264: 16537–

1190 16544.

1191 60. Stukey JE, McDonough VM, Martin CE. The OLE1 gene of *Saccharomyces cerevisiae*

1192 encodes the delta 9 fatty acid desaturase and can be functionally replaced by the rat stearoyl-CoA

1193 desaturase gene. *J Biol Chem.* 1990;265: 20144–20149.

1194 61. Goldar MM, Nishie T, Ishikura Y, Fukuda T, Takegawa K, Kawamukai M. Functional

1195 conservation between fission yeast *moc1/sds23* and its two orthologs, budding yeast *SDS23* and

1196 *SDS24*, and phenotypic differences in their disruptants. *Biosci Biotechnol Biochem.* 2005;69:

1197 1422–1426. doi:10.1271/bbb.69.1422

1198 62. Choi JY, Stukey J, Hwang SY, Martin CE. Regulatory elements that control transcription

1199 activation and unsaturated fatty acid-mediated repression of the *Saccharomyces cerevisiae* OLE1

1200 gene. *J Biol Chem.* 1996;271: 3581–3589. doi:10.1074/jbc.271.7.3581

1201 63. McIsaac RS, Oakes BL, Wang X, Dummit KA, Botstein D, Noyes MB. Synthetic gene

1202 expression perturbation systems with rapid, tunable, single-gene specificity in yeast. *Nucleic*

1203 *Acids Research.* 2013;41: e57–e57.

1204 64. Bergenholm D, Liu G, Holland P, Nielsen J. Reconstruction of a Global Transcriptional

1205 Regulatory Network for Control of Lipid Metabolism in Yeast by Using Chromatin

1206 Immunoprecipitation with Lambda Exonuclease Digestion. *mSystems*. 2018;3: e00215-17.  
1207 doi:10.1128/mSystems.00215-17

1208 65. Bloom JS, Kotenko I, Sadhu MJ, Treusch S, Albert FW, Kruglyak L. Genetic interactions  
1209 contribute less than additive effects to quantitative trait variation in yeast. *Nature*  
1210 *Communications*. 2015;6: 8712.

1211 66. Peter J, Chiara MD, Friedrich A, Yue J-X, Pflieger D, Bergström A, et al. Genome  
1212 evolution across 1,011 *Saccharomyces cerevisiae* isolates. *Nature*. 2018;556: 339–344.  
1213 doi:10.1038/s41586-018-0030-5

1214 67. Wang Q-M, Liu W-Q, Liti G, Wang S-A, Bai F-Y. Surprisingly diverged populations of  
1215 *Saccharomyces cerevisiae* in natural environments remote from human activity. *Molecular*  
1216 *Ecology*. 2012;21: 5404–5417. doi:10.1111/j.1365-294X.2012.05732.x

1217 68. Duan S-F, Han P-J, Wang Q-M, Liu W-Q, Shi J-Y, Li K, et al. The origin and adaptive  
1218 evolution of domesticated populations of yeast from Far East Asia. *Nat Commun*. 2018;9: 1–13.  
1219 doi:10.1038/s41467-018-05106-7

1220 69. Breslow DK, Cameron DM, Collins SR, Schuldiner M, Stewart-Ornstein J, Newman  
1221 HW, et al. A comprehensive strategy enabling high-resolution functional analysis of the yeast  
1222 genome. *Nature Methods*. 2008;5: 711–718. doi:10.1038/nmeth.1234

1223 70. Lee JT, Coradini ALV, Shen A, Ehrenreich IM. Layers of Cryptic Genetic Variation  
1224 Underlie a Yeast Complex Trait. *Genetics*. 2019;211: 1469–1482.  
1225 doi:10.1534/genetics.119.301907

1226 71. Holt S, Kankipati H, De Graeve S, Van Zeebroeck G, Foulquié-Moreno MR, Lindgreen  
1227 S, et al. Major sulfonate transporter Soa1 in *Saccharomyces cerevisiae* and considerable substrate  
1228 diversity in its fungal family. *Nat Commun*. 2017;8. doi:10.1038/ncomms14247

1229 72. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, et al.  
1230 Functional characterization of the *S. cerevisiae* genome by gene deletion and parallel analysis.  
1231 *Science*. 1999;285: 901–906. doi:10.1126/science.285.5429.901

1232 73. Huh W-K, Falvo JV, Gerke LC, Carroll AS, Howson RW, Weissman JS, et al. Global  
1233 analysis of protein localization in budding yeast. *Nature*. 2003;425: 686–691.  
1234 doi:10.1038/nature02026

1235 74. Steinmetz LM, Sinha H, Richards DR, Spiegelman JI, Oefner PJ, McCusker JH, et al.  
1236 Dissecting the architecture of a quantitative trait locus in yeast. *Nature*. 2002;416: 326–330.

1237 75. Sinha H, David L, Pascon RC, Clauder-Münster S, Krishnakumar S, Nguyen M, et al.  
1238 Sequential Elimination of Major-Effect Contributors Identifies Additional Quantitative Trait  
1239 Loci Conditioning High-Temperature Growth in Yeast. *Genetics*. 2008;180: 1661–1670.  
1240 doi:10.1534/genetics.108.092932

1241 76. Fay JC. The molecular basis of phenotypic variation in yeast. *Current opinion in genetics*  
1242 & development

1243 77. GTEx Consortium, Laboratory, Data Analysis &Coordinating Center (LDACC)—  
1244 Analysis Working Group, Statistical Methods groups—Analysis Working Group, Enhancing  
1245 GTEx (eGTEx) groups, NIH Common Fund, NIH/NCI, et al. Genetic effects on gene expression  
1246 across human tissues. *Nature*. 2017;550: 204–213.

1247 78. Westra H-J, Peters MJ, Esko T, Yaghoobkar H, Schurmann C, Kettunen J, et al.  
1248 Systematic identification of trans eQTLs as putative drivers of known disease associations.  
1249 *Nature Genetics*. 2013;45: 1238–1243.

1250 79. Small KS, Todorcevic M, Civelek M, Moustafa JSE-S, Wang X, Simon MM, et al.  
1251 Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on  
1252 adipocyte size and body composition. *Nature Genetics*. 2018;50: 572–+.

1253 80. Heinig M, Petretto E, Wallace C, Bottolo L, Rotival M, Lu H, et al. A trans-acting locus  
1254 regulates an anti-viral expression network and type 1 diabetes risk. *Nature*. 2010;467: 460–464.

1255 81. Yao C, Joehanes R, Johnson AD, Huan T, Liu C, Freedman JE, et al. Dynamic Role of  
1256 trans Regulation of Gene Expression in Relation to Complex Traits. *The American Journal of  
1257 Human Genetics*. 2017;100: 571–580.

1258 82. Yang F, Wang J, Consortium TGte, Pierce BL, Chen LS, Aguet F, et al. Identifying cis-  
1259 mediators for trans-eQTLs across many human tissues using genomic mediation analysis.  
1260 *Genome Res*. 2017;27: 1859–1871. doi:10.1101/gr.216754.116

1261 83. Shan N, Wang Z, Hou L. Identification of trans-eQTLs using mediation analysis with  
1262 multiple mediators. *BMC Bioinformatics*. 2019;20: 126. doi:10.1186/s12859-019-2651-6

1263 84. Pierce BL, Tong L, Chen LS, Rahaman R, Argos M, Jasmine F, et al. Mediation Analysis  
1264 Demonstrates That Trans-eQTLs Are Often Explained by Cis-Mediation: A Genome-Wide  
1265 Analysis among 1,800 South Asians. *PLoS Genetics*. 2014;10.

1266 85. Bryois J, Buil A, Evans DM, Kemp JP, Montgomery SB, Conrad DF, et al. Cis and Trans  
1267 Effects of Human Genomic Variants on Gene Expression. *PLoS Genetics*. 2014;10: e1004461.

1268 86. Wentzell AM, Rowe HC, Hansen BG, Ticconi C, Halkier BA, Kliebenstein DJ. Linking  
1269 Metabolic QTLs with Network and cis-eQTLs Controlling Biosynthetic Pathways. *PLOS*  
1270 *Genetics*. 2007;3: e162. doi:10.1371/journal.pgen.0030162

1271 87. Fairfax BP, Makino S, Radhakrishnan J, Plant K, Leslie S, Dilthey A, et al. Genetics of  
1272 gene expression in primary immune cells identifies cell type–specific master regulators and roles  
1273 of HLA alleles. *Nature Genetics*. 2012;44: 502–510.

1274 88. Degreif D, de Rond T, Bertl A, Keasling JD, Budin I. Lipid engineering reveals  
1275 regulatory roles for membrane fluidity in yeast flocculation and oxygen-limited growth.  
1276 *Metabolic Engineering*. 2017;41: 46–56. doi:10.1016/j.ymben.2017.03.002

1277 89. Li P, Fu X, Zhang L, Li S. CRISPR/Cas-based screening of a gene activation library in  
1278 *Saccharomyces cerevisiae* identifies a crucial role of OLE1 in thermotolerance. *Microbial*  
1279 *Biotechnology*. 2018;0: 1–10. doi:10.1111/1751-7915.13333

1280 90. Fang Z, Chen Z, Wang S, Shi P, Shen Y, Zhang Y, et al. Overexpression of OLE1  
1281 Enhances Cytoplasmic Membrane Stability and Confers Resistance to Cadmium in  
1282 *Saccharomyces cerevisiae*. *Appl Environ Microbiol*. 2017;83: e02319-16.  
1283 doi:10.1128/AEM.02319-16

1284 91. Hoppe T, Matuschewski K, Rape M, Schlenker S, Ulrich HD, Jentsch S. Activation of a  
1285 Membrane-Bound Transcription Factor by Regulated Ubiquitin/Proteasome-Dependent  
1286 Processing. *Cell*. 2000;102: 577–586. doi:10.1016/S0092-8674(00)00080-5

1287 92. Zhang S, Burkett TJ, Yamashita I, Garfinkel DJ. Genetic redundancy between SPT23 and  
1288 MGA2: regulators of Ty-induced mutations and Ty1 transcription in *Saccharomyces cerevisiae*.  
1289 *Molecular and Cellular Biology*. 1997;17: 4718–4729. doi:10.1128/MCB.17.8.4718

1290 93. Covino R, Ballweg S, Stordeur C, Michaelis JB, Puth K, Wernig F, et al. A Eukaryotic  
1291 Sensor for Membrane Lipid Saturation. *Mol Cell*. 2016;63: 49–59.  
1292 doi:10.1016/j.molcel.2016.05.015

1293 94. Duveau F, Toubiana W, Wittkopp PJ. Fitness Effects of Cis-Regulatory Variants in the  
1294 *Saccharomyces cerevisiae* TDH3 Promoter. *Molecular biology and evolution*. 2017;34: 2908–  
1295 2912.

1296 95. Rest JS, Morales CM, Waldron JB, Opulente DA, Fisher J, Moon S, et al. Nonlinear  
1297 Fitness Consequences of Variation in Expression Level of a Eukaryotic Gene. *Molecular biology*  
1298 and evolution. 2013;30: 448–456.

1299 96. Keren L, Hausser J, Lotan-Pompan M, Vainberg Slutskin I, Alisar H, Kaminski S, et al.  
1300 Massively Parallel Interrogation of the Effects of Gene Expression Levels on Fitness. *Cell*.  
1301 2016;166: 1282–1294.e18.  
1302 97. Schaeck B, Emerson JJ, Wang TY, Lu MYJ, Hsieh LC, Li WH. Inheritance of Gene  
1303 Expression Level and Selective Constraints on Trans- and Cis-Regulatory Changes in Yeast.  
1304 *Molecular biology and evolution*. 2013;  
1305 98. Emerson JJ, Hsieh L-C, Sung H-M, Wang T-Y, Huang C-J, Lu HH-S, et al. Natural  
1306 selection on cis and trans regulation in yeasts. *Genome Research*. 2010;20: 826–836.  
1307 99. Shendure J, Balasubramanian S, Church GM, Gilbert W, Rogers J, Schloss JA, et al.  
1308 DNA sequencing at 40: past, present and future. *Nature*. 2017;550: 345–353.  
1309 doi:10.1038/nature24286  
1310 100. Wagih O, Galardini M, Busby BP, Memon D, Typas A, Beltrao P. A resource of variant  
1311 effect predictions of single nucleotide variants in model organisms. *Molecular Systems Biology*.  
1312 2018;14: e8430. doi:10.15252/msb.20188430  
1313 101. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general  
1314 framework for estimating the relative pathogenicity of human genetic variants. *Nature Genetics*.  
1315 2014;46: 310–315.  
1316 102. Majithia AR, Tsuda B, Agostini M, Gnanapradeepan K, Rice R, Peloso G, et al.  
1317 Prospective functional classification of all possible missense variants in PPARG. *Nature*  
1318 *Genetics*. 2016;48: 1570–1575.  
1319 103. Zhou J, Theesfeld CL, Yao K, Chen KM, Wong AK, Troyanskaya OG. Deep learning  
1320 sequence-based ab initio prediction of variant effects on expression and disease risk. *Nat Genet*.  
1321 2018;50: 1171–1179. doi:10.1038/s41588-018-0160-6  
1322 104. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense  
1323 mutations using PolyPhen-2. *Current protocols in human genetics*. 2013;Chapter 7: Unit7.20.  
1324 105. Findlay GM, Boyle EA, Hause RJ, Klein JC, Shendure J. Saturation editing of genomic  
1325 regions by multiplex homology-directed repair. *Nature*. 2014;513: 120–123.  
1326 106. Matreyek KA, Starita LM, Stephany JJ, Martin B, Chiasson MA, Gray VE, et al.  
1327 Multiplex assessment of protein variant abundance by massively parallel sequencing. *Nat Genet*.  
1328 2018;50: 874–882. doi:10.1038/s41588-018-0122-z

1329 107. Klein JC, Keith A, Rice SJ, Shepherd C, Agarwal V, Loughlin J, et al. Functional testing  
1330 of thousands of osteoarthritis-associated variants for regulatory activity. *Nat Commun.* 2019;10:  
1331 1–9. doi:10.1038/s41467-019-10439-y

1332 108. Sharon E, Chen S-AA, Khosla NM, Smith JD, Pritchard JK, Fraser HB. Functional  
1333 Genetic Variants Revealed by Massively Parallel Precise Genome Editing. *Cell.* 2018;175: 544-  
1334 557.e16. doi:10.1016/j.cell.2018.08.057

1335 109. Roy KR, Smith JD, Vonesch SC, Lin G, Tu CS, Lederer AR, et al. Multiplexed precision  
1336 genome editing with trackable genomic barcodes in yeast. *Nature Biotechnology.* 2018;36: 512–  
1337 520. doi:10.1038/nbt.4137

1338 110. Sadhu MJ, Bloom JS, Day L, Siegel JJ, Kosuri S, Kruglyak L. Highly parallel genome  
1339 variant engineering with CRISPR–Cas9. *Nat Genet.* 2018;50: 510–514. doi:10.1038/s41588-018-  
1340 0087-y

1341 111. Garst AD, Bassalo MC, Pines G, Lynch SA, Halweg-Edwards AL, Liu R, et al. Genome-  
1342 wide mapping of mutations at single-nucleotide resolution for protein, metabolic and genome  
1343 engineering. *Nature Biotechnology.* 2017;35: 48–55.

1344 112. Bao Z, Hamedirad M, Xue P, Xiao H, Tasan I, Chao R, et al. Genome-scale engineering  
1345 of *Saccharomyces cerevisiae* with single-nucleotide precision. *Nature Biotechnology.* 2018;36:  
1346 505–508. doi:10.1038/nbt.4132

1347 113. Guo X, Chavez A, Tung A, Chan Y, Kaas C, Yin Y, et al. High-throughput creation and  
1348 functional profiling of DNA sequence variant libraries using CRISPR–Cas9 in yeast. *Nature  
1349 Biotechnology.* 2018;36: 540–546. doi:10.1038/nbt.4147

1350 114. Starita LM, Ahituv N, Dunham MJ, Kitzman JO, Roth FP, Seelig G, et al. Variant  
1351 Interpretation: Functional Assays to the Rescue. *The American Journal of Human Genetics.*  
1352 2017;101: 315–325. doi:10.1016/j.ajhg.2017.07.014

1353 115. Sheff MA, Thorn KS. Optimized cassettes for fluorescent protein tagging in  
1354 *Saccharomyces cerevisiae*. *Yeast.* 2004;21: 661–670. doi:10.1002/yea.1130

1355 116. Sikorski RS, Hieter P. A system of shuttle vectors and yeast host strains designed for  
1356 efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics.* 1989;122: 19–27.

1357 117. Malcova I, Farkasovsky M, Senohrabkova L, Vasicova P, Hasek J. New integrative  
1358 modules for multicolor-protein labeling and live-cell imaging in *Saccharomyces cerevisiae*.  
1359 *FEMS Yeast Res.* 2016;16. doi:10.1093/femsyr/fow027

1360 118. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without  
1361 the use of restriction enzymes: gene splicing by overlap extension. *Gene*. 1989;77: 61–68.  
1362 doi:10.1016/0378-1119(89)90359-4

1363 119. Gietz RD, Schiestl RH. High-efficiency yeast transformation using the LiAc/SS carrier  
1364 DNA/PEG method. *Nature Protocols*. 2007;2: 31–34.

1365 120. Persson X-MT, Błachnio-Zabielska AU, Jensen MD. Rapid measurement of plasma free  
1366 fatty acid concentration and isotopic enrichment using LC/MS. *J Lipid Res*. 2010;51: 2761–  
1367 2765. doi:10.1194/jlr.M008011

1368 121. Paradis E, Schliep K. ape 5.0: an environment for modern phylogenetics and evolutionary  
1369 analyses in R. *Bioinformatics*. 2018;35: 526–528.

1370 122. Liti G, Carter DM, Moses AM, Warringer J, Parts L, James SA, et al. Population  
1371 genomics of domestic and wild yeasts. *Nature*. 2009;458: 337–341.

1372 123. Wickham H. *ggplot2: Elegant Graphics for Data Analysis* [Internet]. Springer-Verlag  
1373 New York; 2016. Available: <https://ggplot2.tidyverse.org>

1374 124. Sprouffske K, Wagner A. Growthcurver: an R package for obtaining interpretable metrics  
1375 from microbial growth curves. *BMC Bioinformatics*. 2016;17: 172. doi:10.1186/s12859-016-  
1376 1016-7

1377 125. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using  
1378 *lme4*. *Journal of Statistical Software*. 2015;67: 1–48. doi:10.18637/jss.v067.i01

1379 126. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence  
1380 data. *Bioinformatics*. 2014;30: 2114–2120.

1381 127. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq  
1382 quantification. *Nature Biotechnology*. 2016;34: 525–527.

1383 128. Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, et al. Ensembl 2018.  
1384 *Nucleic Acids Res*. 2018;46: D754–D761. doi:10.1093/nar/gkx1098

1385 129. Engel SR, Dietrich FS, Fisk DG, Binkley G, Balakrishnan R, Costanzo MC, et al. The  
1386 Reference Genome Sequence of *Saccharomyces cerevisiae*: Then and Now. *G3: Genes,*  
1387 *Genomes, Genetics*. 2014;4: 389–398. doi:10.1534/g3.113.008995

1388 130. Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, et al. A  
1389 survey of best practices for RNA-seq data analysis. *Genome Biology*. 2016;17: 13.  
1390 doi:10.1186/s13059-016-0881-8

1391 131. Andrews S, others. FastQC: a quality control tool for high throughput sequence data.

1392 Babraham Bioinformatics, Babraham Institute, Cambridge, United Kingdom; 2010.

1393 132. Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments.

1394 Bioinformatics. 2012;28: 2184–2185. doi:10.1093/bioinformatics/bts356

1395 133. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for

1396 RNA-seq data with DESeq2. Genome Biology. 2014;15: 550. doi:10.1186/s13059-014-0550-8

1397 134. Leek JT, Storey JD. Capturing Heterogeneity in Gene Expression Studies by Surrogate

1398 Variable Analysis. PLoS Genetics. 2007;3: e161.

1399 135. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful

1400 approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological).

1401 1995; 289–300.

1402 136. Cherry JM, Hong EL, Amundsen C, Balakrishnan R, Binkley G, Chan ET, et al.

1403 Saccharomyces Genome Database: the genomics resource of budding yeast. Nucleic Acids

1404 Research. 2012;40: D700–D705.

1405

1406 **Supporting information captions**

1407 **S1 Fig. Guide RNA recognition sequences.** A. Schematic of a cassette typically used for gene  
1408 deletions. The gCASS5a recognition sequence is marked with a bracket and the PAM site is  
1409 underlined. Start of the TEF promoter sequence driving expression of the selectable marker is in  
1410 red letters. B. Schematic of a cassette used for C-terminally tagging open reading frames with  
1411 GFP. The location of the gGFP recognition sequence is marked with a bracket and the PAM site  
1412 is underlined. The start of the GFP sequence is in neon green. The recognition sites for Sall (pink)  
1413 and PacI (purple) are the Cas9 cleavage sites (scissors) are shown to allow easy comparison of the  
1414 gRNA recognition sequences, which are specific to each cassette. Designated with arrows are the  
1415 universal primer sequences, S1 or U2 and F1, used for amplification of common cassettes.

1416

1417 **S2 Fig. *OAF1* fine mapping.** On the left are schematics of *OAF1* alleles with BY sequences in  
1418 blue and RM sequences in red. Missense variants are marked with a straight line. Synonymous and  
1419 non-coding variants are not shown. On the right are the corresponding Faa4-GFP fluorescence  
1420 levels for each allele. P-values are for tests comparing each allele to its respective wildtype.  
1421 Significant p-values are outlined. Blue boxplots indicate alleles in the BY background and red  
1422 boxplots and background gray shading indicate alleles in the RM background. Lines group  
1423 measurements of the same clone. Different symbols (circles, squares, etc.) denote different plate  
1424 reader runs.

1425

1426 **S3 Fig. *OLE1* fine mapping.** On the left are schematics of *OLE1* alleles with BY sequences in  
1427 blue and RM sequences in red. Only the one missense variant and none of the synonymous variants  
1428 in the open reading frame are marked. Variants in the non-coding region are marked with a single  
1429 line for a SNV and two diagonal lines for INDELS. On the right are the corresponding Faa4-GFP  
1430 fluorescence levels for each allele. P-values are for tests comparing each allele to its respective  
1431 wildtype. Significant p-values are outlined. Blue boxplots indicate alleles in the BY background  
1432 and red boxplots and background gray shading indicate alleles in the RM background. Lines group  
1433 measurements of the same clone. Different symbols (circles, squares, etc.) denote different plate  
1434 reader runs.

1435

1436 **S4 Fig. yeVenus reporter expression.** On the top are schematics of the SDS23/OLE1 locus and  
1437 the two orientations of the yeVenus reporter constructs. The bottom panel shows yeVenus  
1438 fluorescence levels for the indicated yeVenus reporter constructs. Blue boxplots indicate alleles in  
1439 the BY background and red boxplots indicate alleles in the RM background. Lines group  
1440 measurements of the same clone. Different symbols (circles, squares, etc.) denote different plate  
1441 reader runs.

1442

1443 **S5 Fig. Effects of plasmid overexpression of SDS23/OLE1 sequences on Faa4-GFP**  
1444 **expression.** Faa4-GFP fluorescence levels of strains transformed with a *LEU2*-CEN plasmid  
1445 containing the indicated sequence. Lines group measurements of the same clone.

1446

1447 **S6 Fig. Growth rates as a function of estradiol dose.** Error bars show standard deviations.

1448

1449 **S7 Fig. Lipid and fatty acid measurements.** All individual measurements are shown. For each  
1450 genotype, the figure shows values for each replicate (smaller points) along with the mean (larger  
1451 points) and standard deviation (vertical lines).

1452

1453 **S1 Table. Fine-mapping p-values**

1454 **S2 Table. Lipid measurements**

1455 **S3 Table. Lipid statistics**

1456 **S4 Table. RNA sequencing gene expression counts**

1457 **S5 Table. RNA sequencing sample and batch information**

1458 **S6 Table. RNA sequencing results**

1459 **S7 Table. eQTL hotspot literature review**

1460 **S8 Table. Yeast strains**

1461 **S9 Table. Plasmids**

1462 **S10 Table. Oligos**

1463 **S11 Table. Yeast strain and plasmid construction**